[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fmrkChKlo89gGI7Q5Nd2YmZOCdejWONcU3Jah6EUjHTQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":84,"rows":91},"National Institute of Mental Health (NIMH)",[4],360,false,43,10,148890,16,208,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Healthy",63,{"name":18,"count":19},"Depression",47,{"name":21,"count":22},"Bipolar Disorder",34,{"name":24,"count":22},"Schizophrenia",{"name":26,"count":27},"Major Depressive Disorder",18,{"name":29,"count":11},"Mood Disorder",{"name":31,"count":32},"Anxiety Disorders",14,{"name":34,"count":35},"Mood Disorders",13,[37,42,47,52,56,60,65,70,75,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03065335","Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder","2027-01-01","Ketamine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03973268","Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression","2027-02-01","Arm 1, 2, 3 drug Interventions",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT06874205","Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers","2028-02-22","11C-JMJ-129",{"nctId":53,"briefTitle":54,"date":50,"intervention":55},"NCT07027839","Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)","Intravenous Ethanol",{"nctId":57,"briefTitle":58,"date":50,"intervention":59},"NCT06920628","PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)","11C-PS13",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05703685","[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET","2028-10-03","Apremilast",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT06795581","PET Imaging of Phosphodiesterase-4B (PDE4B) in Alcohol Use Disorder","2028-12-11","18F-PF-06445974",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT00018057","Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders","2029-01-01","Fluoxetine",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT07169630","PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)","2029-04-11","18F-PF974",{"nctId":81,"briefTitle":82,"date":78,"intervention":83},"NCT04396873","PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease","11C-MC1",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,120,169,204,253,280,315,347,368,386,408,426,451,469,487,505,561,632,677,713,753,775,802,827,852,878,896,914,932,950,968,986,1004,1022,1045,1063,1081,1099,1117,1135,1162,1187,1205,1229,1247,1275,1299,1317,1335,1359,1387,1412,1466,1504,1553,1586,1612,1634,1655,1678,1703,1727,1749,1773,1797,1821,1847,1865,1893,1911,1934,1958,1981,2005,2030,2054,2072,2095,2119,2143,2169,2187,2210,2235,2253,2277,2300,2323,2341,2359,2382,2406,2424,2447,2472,2496,2519,2537,2562,2586,2604,2626,2652,2670,2693,2715,2739,2757,2788,2812,2835,2858,2883,2901,2925,2948,2972,2995,3020,3038,3065,3083,3101,3125,3150,3168,3191,3212,3240,3262,3284,3308,3331,3354,3377,3400,3426,3449,3472,3495,3518,3543,3582,3625,3664,3693,3732,3758,3780,3802,3830,3859,3881,3904,3926,3948,3976,4000,4024,4042,4060,4084,4102,4127,4150,4172,4197,4220,4243,4261,4282,4303,4321,4339,4357],{"intervention":93,"totalTrials":94,"cells":95},"Ketamine Hydrochloride",1,{"EARLY_PHASE1":96,"PHASE1":99,"PHASE2":101,"PHASE3":114,"PHASE4":116,"NA":118},{"trials":97,"activeCount":98},[],0,{"trials":100,"activeCount":98},[],{"trials":102,"activeCount":94,"soonestReadout":108},[103],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT02543983","Neurobiology of Suicide","RECRUITING",[87],"2030-07-21","2015-12-01",325,[112,18],"Healthy Volunteers",[93],{"trials":115,"activeCount":98},[],{"trials":117,"activeCount":98},[],{"trials":119,"activeCount":98},[],{"intervention":74,"totalTrials":121,"cells":122},4,{"EARLY_PHASE1":123,"PHASE1":125,"PHASE2":127,"PHASE3":135,"PHASE4":155,"NA":157},{"trials":124,"activeCount":98},[],{"trials":126,"activeCount":98},[],{"trials":128,"activeCount":94,"soonestReadout":73},[129],{"nctId":71,"briefTitle":72,"status":106,"phases":130,"primaryCompletion":73,"completion":73,"start":131,"enrollment":132,"conditions":133,"interventions":134},[87],"2001-10-02",3500,[31,26],[74],{"trials":136,"activeCount":98},[137,147],{"nctId":138,"briefTitle":139,"status":140,"phases":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":146},"NCT00006286","Treatment for Adolescents With Depression Study (TADS)","COMPLETED",[88],"2004-03","1998-09",432,[26,18],[74],{"nctId":148,"briefTitle":149,"status":150,"phases":151,"completion":152,"conditions":153,"interventions":154},"NCT00005015","Treatment of Depression in Youth With Bipolar Disorders","TERMINATED",[88],"2000-09",[21,18],[74],{"trials":156,"activeCount":98},[],{"trials":158,"activeCount":98},[159],{"nctId":160,"briefTitle":161,"status":140,"phases":162,"start":163,"enrollment":164,"conditions":165,"interventions":167},"NCT00004446","Study of Fluoxetine in Patients With Depersonalization Disorder",[90],"1998-04",80,[166],"Depersonalization Disorder",[168],"fluoxetine",{"intervention":69,"totalTrials":170,"cells":171},3,{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":173,"activeCount":98},[],{"trials":175,"activeCount":170,"soonestReadout":50},[176,184,190],{"nctId":66,"briefTitle":67,"status":106,"phases":177,"primaryCompletion":68,"completion":178,"start":179,"enrollment":180,"conditions":181,"interventions":183},[86],"2029-01-31","2025-03-20",30,[182],"Alcohol Use Disorder",[69],{"nctId":61,"briefTitle":62,"status":106,"phases":185,"primaryCompletion":63,"completion":78,"start":186,"enrollment":187,"conditions":188,"interventions":189},[86],"2023-06-22",108,[18],[64,69],{"nctId":53,"briefTitle":54,"status":106,"phases":191,"primaryCompletion":50,"completion":192,"start":193,"enrollment":180,"conditions":194,"interventions":195},[86],"2029-02-22","2025-12-11",[182],[55,69],{"trials":197,"activeCount":98},[],{"trials":199,"activeCount":98},[],{"trials":201,"activeCount":98},[],{"trials":203,"activeCount":98},[],{"intervention":59,"totalTrials":170,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":232,"PHASE3":247,"PHASE4":249,"NA":251},{"trials":207,"activeCount":98},[],{"trials":209,"activeCount":231,"soonestReadout":50},[210,223],{"nctId":81,"briefTitle":82,"status":106,"phases":211,"primaryCompletion":78,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":221},[86],"2030-10-03","2021-08-17",184,[216,217,218,219,220],"Parkinson's Disease","Dementia","Alzheimer's Disease","ALS","Mild Cognitive Impairment",[83,59,222],"18f-florbetaben",{"nctId":57,"briefTitle":58,"status":106,"phases":224,"primaryCompletion":50,"completion":192,"start":225,"enrollment":226,"conditions":227,"interventions":230},[86],"2025-06-18",60,[228,229],"Long COVID","Post Acute Sequelae of COVID-19",[59],2,{"trials":233,"activeCount":98},[234],{"nctId":235,"briefTitle":236,"status":150,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT05062083","PET Imaging of Cyclooxygenase in Multiple Sclerosis",[87],"2023-09-05","2024-01-30","2022-06-07",7,[243],"Multiple Sclerosis",[83,59,245,246],"Ketoprofen","Celecoxib",{"trials":248,"activeCount":98},[],{"trials":250,"activeCount":98},[],{"trials":252,"activeCount":98},[],{"intervention":254,"totalTrials":231,"cells":255},"18F-florbetaben",{"EARLY_PHASE1":256,"PHASE1":258,"PHASE2":272,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":257,"activeCount":98},[],{"trials":259,"activeCount":231,"soonestReadout":78},[260,268],{"nctId":76,"briefTitle":77,"status":106,"phases":261,"primaryCompletion":78,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":267},[86],"2030-04-11","2026-06-07",90,[266,220,15],"Alzheimer s Disease",[79,254],{"nctId":81,"briefTitle":82,"status":106,"phases":269,"primaryCompletion":78,"completion":212,"start":213,"enrollment":214,"conditions":270,"interventions":271},[86],[216,217,218,219,220],[83,59,222],{"trials":273,"activeCount":98},[],{"trials":275,"activeCount":98},[],{"trials":277,"activeCount":98},[],{"trials":279,"activeCount":98},[],{"intervention":83,"totalTrials":170,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":303,"PHASE3":309,"PHASE4":311,"NA":313},{"trials":283,"activeCount":98},[],{"trials":285,"activeCount":94,"soonestReadout":78},[286,299],{"nctId":287,"briefTitle":288,"status":150,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":297},"NCT03912428","Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions",[86],"2024-06-14","2019-06-14",31,[294,295,296,112],"Myositis","Inflammatory","Rheumatoid Arthritis",[83,246,298],"[11C]ER176",{"nctId":81,"briefTitle":82,"status":106,"phases":300,"primaryCompletion":78,"completion":212,"start":213,"enrollment":214,"conditions":301,"interventions":302},[86],[216,217,218,219,220],[83,59,222],{"trials":304,"activeCount":98},[305],{"nctId":235,"briefTitle":236,"status":150,"phases":306,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":307,"interventions":308},[87],[243],[83,59,245,246],{"trials":310,"activeCount":98},[],{"trials":312,"activeCount":98},[],{"trials":314,"activeCount":98},[],{"intervention":41,"totalTrials":231,"cells":316},{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":329,"PHASE3":341,"PHASE4":343,"NA":345},{"trials":318,"activeCount":98},[],{"trials":320,"activeCount":94,"soonestReadout":40},[321],{"nctId":38,"briefTitle":39,"status":106,"phases":322,"primaryCompletion":40,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},[86],"2028-01-01","2017-05-25",150,[327,26,18],"Healthy Volunteer",[41],{"trials":330,"activeCount":98},[331],{"nctId":332,"briefTitle":333,"status":140,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT00088699","Rapid Antidepressant Effects of Ketamine in Major Depression",[86,87],"2017-07-31","2004-07-26",67,[18,34,339],"Major Depresssion",[41],{"trials":342,"activeCount":98},[],{"trials":344,"activeCount":98},[],{"trials":346,"activeCount":98},[],{"intervention":51,"totalTrials":94,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":360,"PHASE3":362,"PHASE4":364,"NA":366},{"trials":350,"activeCount":98},[],{"trials":352,"activeCount":94,"soonestReadout":50},[353],{"nctId":48,"briefTitle":49,"status":106,"phases":354,"primaryCompletion":50,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":359},[86],"2029-02-05","2025-04-11",40,[15],[51],{"trials":361,"activeCount":98},[],{"trials":363,"activeCount":98},[],{"trials":365,"activeCount":98},[],{"trials":367,"activeCount":98},[],{"intervention":79,"totalTrials":94,"cells":369},{"EARLY_PHASE1":370,"PHASE1":372,"PHASE2":378,"PHASE3":380,"PHASE4":382,"NA":384},{"trials":371,"activeCount":98},[],{"trials":373,"activeCount":94,"soonestReadout":78},[374],{"nctId":76,"briefTitle":77,"status":106,"phases":375,"primaryCompletion":78,"completion":262,"start":263,"enrollment":264,"conditions":376,"interventions":377},[86],[266,220,15],[79,254],{"trials":379,"activeCount":98},[],{"trials":381,"activeCount":98},[],{"trials":383,"activeCount":98},[],{"trials":385,"activeCount":98},[],{"intervention":46,"totalTrials":94,"cells":387},{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":400,"PHASE3":402,"PHASE4":404,"NA":406},{"trials":389,"activeCount":98},[],{"trials":391,"activeCount":94,"soonestReadout":45},[392],{"nctId":43,"briefTitle":44,"status":106,"phases":393,"primaryCompletion":45,"completion":45,"start":394,"enrollment":395,"conditions":396,"interventions":398},[86],"2020-01-21",70,[18,26,397],"Major Depression",[46,399],"Arm 1 and 2 Interventions",{"trials":401,"activeCount":98},[],{"trials":403,"activeCount":98},[],{"trials":405,"activeCount":98},[],{"trials":407,"activeCount":98},[],{"intervention":399,"totalTrials":94,"cells":409},{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":418,"PHASE3":420,"PHASE4":422,"NA":424},{"trials":411,"activeCount":98},[],{"trials":413,"activeCount":94,"soonestReadout":45},[414],{"nctId":43,"briefTitle":44,"status":106,"phases":415,"primaryCompletion":45,"completion":45,"start":394,"enrollment":395,"conditions":416,"interventions":417},[86],[18,26,397],[46,399],{"trials":419,"activeCount":98},[],{"trials":421,"activeCount":98},[],{"trials":423,"activeCount":98},[],{"trials":425,"activeCount":98},[],{"intervention":427,"totalTrials":94,"cells":428},"11C-MCI",{"EARLY_PHASE1":429,"PHASE1":431,"PHASE2":443,"PHASE3":445,"PHASE4":447,"NA":449},{"trials":430,"activeCount":98},[],{"trials":432,"activeCount":94,"soonestReadout":437},[433],{"nctId":434,"briefTitle":435,"status":106,"phases":436,"primaryCompletion":437,"completion":262,"start":438,"enrollment":439,"conditions":440,"interventions":441},"NCT04582916","PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)",[86],"2029-10-03","2021-07-20",64,[18],[427,442],"11CPS13",{"trials":444,"activeCount":98},[],{"trials":446,"activeCount":98},[],{"trials":448,"activeCount":98},[],{"trials":450,"activeCount":98},[],{"intervention":442,"totalTrials":94,"cells":452},{"EARLY_PHASE1":453,"PHASE1":455,"PHASE2":461,"PHASE3":463,"PHASE4":465,"NA":467},{"trials":454,"activeCount":98},[],{"trials":456,"activeCount":94,"soonestReadout":437},[457],{"nctId":434,"briefTitle":435,"status":106,"phases":458,"primaryCompletion":437,"completion":262,"start":438,"enrollment":439,"conditions":459,"interventions":460},[86],[18],[427,442],{"trials":462,"activeCount":98},[],{"trials":464,"activeCount":98},[],{"trials":466,"activeCount":98},[],{"trials":468,"activeCount":98},[],{"intervention":64,"totalTrials":94,"cells":470},{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":479,"PHASE3":481,"PHASE4":483,"NA":485},{"trials":472,"activeCount":98},[],{"trials":474,"activeCount":94,"soonestReadout":63},[475],{"nctId":61,"briefTitle":62,"status":106,"phases":476,"primaryCompletion":63,"completion":78,"start":186,"enrollment":187,"conditions":477,"interventions":478},[86],[18],[64,69],{"trials":480,"activeCount":98},[],{"trials":482,"activeCount":98},[],{"trials":484,"activeCount":98},[],{"trials":486,"activeCount":98},[],{"intervention":55,"totalTrials":94,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":497,"PHASE3":499,"PHASE4":501,"NA":503},{"trials":490,"activeCount":98},[],{"trials":492,"activeCount":94,"soonestReadout":50},[493],{"nctId":53,"briefTitle":54,"status":106,"phases":494,"primaryCompletion":50,"completion":192,"start":193,"enrollment":180,"conditions":495,"interventions":496},[86],[182],[55,69],{"trials":498,"activeCount":98},[],{"trials":500,"activeCount":98},[],{"trials":502,"activeCount":98},[],{"trials":504,"activeCount":98},[],{"intervention":506,"totalTrials":170,"cells":507},"Lithium",{"EARLY_PHASE1":508,"PHASE1":510,"PHASE2":512,"PHASE3":514,"PHASE4":516,"NA":536},{"trials":509,"activeCount":98},[],{"trials":511,"activeCount":98},[],{"trials":513,"activeCount":98},[],{"trials":515,"activeCount":98},[],{"trials":517,"activeCount":98},[518],{"nctId":519,"briefTitle":520,"status":140,"phases":521,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":526},"NCT00021528","Sequenced Treatment Alternatives to Relieve Depression (STAR*D)",[89],"2006-09","2001-07",4000,[18],[527,528,529,506,530,531,532,533,534,535],"citalopram","BuproprionSR","buspirone","mirtazapine","nortriptyline","sertraline","tranylcypromine","VenlafaxineXR","T3",{"trials":537,"activeCount":94},[538,553],{"nctId":539,"briefTitle":540,"status":140,"phases":541,"completion":542,"start":143,"enrollment":543,"conditions":544,"interventions":545},"NCT00012558","Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)",[90],"2005-09",5000,[21],[546,547,548,549,550,551,552,533],"lithium","valproate","bupropion","paroxetine","lamotrigine","risperidone","inositol",{"nctId":554,"briefTitle":555,"status":106,"phases":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT00025935","Studies of Brain Function and Course of Illness in Pediatric Bipolar Disorder",[],"2002-01-01",2350,[29],[506],{"intervention":562,"totalTrials":563,"cells":564},"Clozapine",5,{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":580,"PHASE4":591,"NA":630},{"trials":566,"activeCount":98},[],{"trials":568,"activeCount":98},[],{"trials":570,"activeCount":98},[571],{"nctId":572,"briefTitle":573,"status":140,"phases":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},"NCT00029458","Clozapine for Treatment-Resistant Mania",[87],"2005-10","2002-01",42,[21],[562],{"trials":581,"activeCount":98},[582],{"nctId":583,"briefTitle":584,"status":140,"phases":585,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":590},"NCT00036582","Clozapine vs. Placebo in Treatment-Refractory Bipolar Disorder in Children and Adolescents",[88],"2004-02","2002-05",116,[21],[562],{"trials":592,"activeCount":98},[593,605,615],{"nctId":594,"briefTitle":595,"status":140,"phases":596,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":600,"interventions":603},"NCT00001656","Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders",[89],"2008-06","1997-06",25,[601,602,24],"Childhood Schizophrenia","Psychotic Disorder",[604,562],"Olanzapine",{"nctId":606,"briefTitle":607,"status":140,"phases":608,"completion":609,"start":610,"enrollment":226,"conditions":611,"interventions":613},"NCT00031317","Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression",[89],"2005-06","2002-02",[612],"Panic Disorder",[614,562],"Paroxetine",{"nctId":616,"briefTitle":617,"status":140,"phases":618,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":623},"NCT00014001","CATIE- Schizophrenia Trial",[89],"2004-12","2000-12",1600,[24],[624,625,626,551,627,628,629],"perphenazine","olanzapine","quetiapine","ziprasidone","clozapine","fluphenazine decanoate",{"trials":631,"activeCount":98},[],{"intervention":633,"totalTrials":170,"cells":634},"Propranolol",{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":660,"PHASE4":662,"NA":675},{"trials":636,"activeCount":98},[],{"trials":638,"activeCount":98},[],{"trials":640,"activeCount":98},[641,650],{"nctId":642,"briefTitle":643,"status":140,"phases":644,"completion":645,"start":646,"enrollment":395,"conditions":647,"interventions":649},"NCT00016666","Clinical Trial of Propranolol for Seasonal Affective Disorder",[87],"2007-01-19","2001-05-21",[648,15],"Seasonal Affective Disorder",[633],{"nctId":651,"briefTitle":652,"status":140,"phases":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":659},"NCT00069355","Propranolol for the Treatment of Acute Stress Disorder",[87],"2004-10","2003-09",50,[658],"Stress Disorders, Traumatic, Acute",[633],{"trials":661,"activeCount":98},[],{"trials":663,"activeCount":98},[664],{"nctId":665,"briefTitle":666,"status":140,"phases":667,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":671,"interventions":673},"NCT02153944","Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety",[89],"2021-10-07","2014-06-16",142,[672],"Anxiety Disorder",[633,674],"Methylphenidate",{"trials":676,"activeCount":98},[],{"intervention":678,"totalTrials":231,"cells":679},"Escitalopram",{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":696,"PHASE4":698,"NA":711},{"trials":681,"activeCount":98},[],{"trials":683,"activeCount":98},[],{"trials":685,"activeCount":98},[686],{"nctId":687,"briefTitle":688,"status":140,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":694},"NCT00086307","Lexapro and Pramipexole and to Treat Major Depression",[87],"2010-03","2004-06",39,[397],[695,678],"Pramipexole",{"trials":697,"activeCount":98},[],{"trials":699,"activeCount":98},[700],{"nctId":701,"briefTitle":702,"status":140,"phases":703,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":708,"interventions":709},"NCT00375843","Brain Activity Changes and Treatment Response in Depressed People Who Are Receiving Antidepressant Medication",[89],"2007-06","2008-03","2005-01",118,[18],[678,710],"Sertraline",{"trials":712,"activeCount":98},[],{"intervention":714,"totalTrials":231,"cells":715},"Aripiprazole",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":751},{"trials":717,"activeCount":98},[],{"trials":719,"activeCount":98},[],{"trials":721,"activeCount":98},[],{"trials":723,"activeCount":98},[],{"trials":725,"activeCount":98},[726,738],{"nctId":727,"briefTitle":728,"status":140,"phases":729,"primaryCompletion":730,"completion":690,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT00423878","Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder",[89],"2009-10","2007-01",215,[24,734],"Schizoaffective Disorder",[736,604,737,714],"Risperidone","Quetiapine",{"nctId":739,"briefTitle":740,"status":140,"phases":741,"primaryCompletion":742,"completion":730,"start":743,"enrollment":744,"conditions":745,"interventions":746},"NCT00802100","Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia",[89],"2009-09","2008-12",21,[24],[604,747,714,748,749,750],"Perphenazine","Metformin","Simvastatin","Benztropine",{"trials":752,"activeCount":98},[],{"intervention":624,"totalTrials":231,"cells":754},{"EARLY_PHASE1":755,"PHASE1":757,"PHASE2":759,"PHASE3":761,"PHASE4":763,"NA":773},{"trials":756,"activeCount":98},[],{"trials":758,"activeCount":98},[],{"trials":760,"activeCount":98},[],{"trials":762,"activeCount":98},[],{"trials":764,"activeCount":98},[765,769],{"nctId":616,"briefTitle":617,"status":140,"phases":766,"completion":619,"start":620,"enrollment":621,"conditions":767,"interventions":768},[89],[24],[624,625,626,551,627,628,629],{"nctId":739,"briefTitle":740,"status":140,"phases":770,"primaryCompletion":742,"completion":730,"start":743,"enrollment":744,"conditions":771,"interventions":772},[89],[24],[604,747,714,748,749,750],{"trials":774,"activeCount":98},[],{"intervention":748,"totalTrials":231,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":800},{"trials":778,"activeCount":98},[],{"trials":780,"activeCount":98},[],{"trials":782,"activeCount":98},[],{"trials":784,"activeCount":98},[],{"trials":786,"activeCount":98},[787,791],{"nctId":739,"briefTitle":740,"status":140,"phases":788,"primaryCompletion":742,"completion":730,"start":743,"enrollment":744,"conditions":789,"interventions":790},[89],[24],[604,747,714,748,749,750],{"nctId":792,"briefTitle":793,"status":140,"phases":794,"primaryCompletion":795,"completion":690,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT00816907","The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)",[89],"2010-02","2009-01",146,[24],[748],{"trials":801,"activeCount":98},[],{"intervention":803,"totalTrials":94,"cells":804},"Alendronate",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":825},{"trials":806,"activeCount":98},[],{"trials":808,"activeCount":98},[],{"trials":810,"activeCount":98},[],{"trials":812,"activeCount":98},[],{"trials":814,"activeCount":98},[815],{"nctId":816,"briefTitle":817,"status":140,"phases":818,"completion":645,"start":819,"enrollment":820,"conditions":821,"interventions":824},"NCT00006180","Bone Loss in Premenopausal Women With Depression",[89],"2000-08-10",220,[18,15,822,823],"Osteopenia","Osteoporosis",[803],{"trials":826,"activeCount":98},[],{"intervention":828,"totalTrials":94,"cells":829},"clonazepam and paroxetine",{"EARLY_PHASE1":830,"PHASE1":832,"PHASE2":834,"PHASE3":836,"PHASE4":838,"NA":850},{"trials":831,"activeCount":98},[],{"trials":833,"activeCount":98},[],{"trials":835,"activeCount":98},[],{"trials":837,"activeCount":98},[],{"trials":839,"activeCount":98},[840],{"nctId":841,"briefTitle":842,"status":140,"phases":843,"completion":844,"start":845,"enrollment":846,"conditions":847,"interventions":849},"NCT00025740","Clonazepam and Paroxetine for Rapid Treatment of Post-Traumatic Stress Disorder",[89],"2004-08","2001-10",78,[848],"Post Traumatic Stress Disorder",[828],{"trials":851,"activeCount":98},[],{"intervention":853,"totalTrials":94,"cells":854},"Raloxifene",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":876},{"trials":856,"activeCount":98},[],{"trials":858,"activeCount":98},[],{"trials":860,"activeCount":98},[],{"trials":862,"activeCount":98},[],{"trials":864,"activeCount":98},[865],{"nctId":866,"briefTitle":867,"status":140,"phases":868,"primaryCompletion":869,"completion":869,"start":610,"enrollment":870,"conditions":871,"interventions":873},"NCT00030147","Raloxifene and Rimostil for Perimenopause-Related Depression",[89],"2015-06",65,[872,18],"Perimenopausal Depression",[853,874,875],"Rimostil","Transdermal Estradiol",{"trials":877,"activeCount":98},[],{"intervention":874,"totalTrials":94,"cells":879},{"EARLY_PHASE1":880,"PHASE1":882,"PHASE2":884,"PHASE3":886,"PHASE4":888,"NA":894},{"trials":881,"activeCount":98},[],{"trials":883,"activeCount":98},[],{"trials":885,"activeCount":98},[],{"trials":887,"activeCount":98},[],{"trials":889,"activeCount":98},[890],{"nctId":866,"briefTitle":867,"status":140,"phases":891,"primaryCompletion":869,"completion":869,"start":610,"enrollment":870,"conditions":892,"interventions":893},[89],[872,18],[853,874,875],{"trials":895,"activeCount":98},[],{"intervention":875,"totalTrials":94,"cells":897},{"EARLY_PHASE1":898,"PHASE1":900,"PHASE2":902,"PHASE3":904,"PHASE4":906,"NA":912},{"trials":899,"activeCount":98},[],{"trials":901,"activeCount":98},[],{"trials":903,"activeCount":98},[],{"trials":905,"activeCount":98},[],{"trials":907,"activeCount":98},[908],{"nctId":866,"briefTitle":867,"status":140,"phases":909,"primaryCompletion":869,"completion":869,"start":610,"enrollment":870,"conditions":910,"interventions":911},[89],[872,18],[853,874,875],{"trials":913,"activeCount":98},[],{"intervention":528,"totalTrials":94,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":922,"PHASE4":924,"NA":930},{"trials":917,"activeCount":98},[],{"trials":919,"activeCount":98},[],{"trials":921,"activeCount":98},[],{"trials":923,"activeCount":98},[],{"trials":925,"activeCount":98},[926],{"nctId":519,"briefTitle":520,"status":140,"phases":927,"completion":522,"start":523,"enrollment":524,"conditions":928,"interventions":929},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":931,"activeCount":98},[],{"intervention":529,"totalTrials":94,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":948},{"trials":935,"activeCount":98},[],{"trials":937,"activeCount":98},[],{"trials":939,"activeCount":98},[],{"trials":941,"activeCount":98},[],{"trials":943,"activeCount":98},[944],{"nctId":519,"briefTitle":520,"status":140,"phases":945,"completion":522,"start":523,"enrollment":524,"conditions":946,"interventions":947},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":949,"activeCount":98},[],{"intervention":530,"totalTrials":94,"cells":951},{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":966},{"trials":953,"activeCount":98},[],{"trials":955,"activeCount":98},[],{"trials":957,"activeCount":98},[],{"trials":959,"activeCount":98},[],{"trials":961,"activeCount":98},[962],{"nctId":519,"briefTitle":520,"status":140,"phases":963,"completion":522,"start":523,"enrollment":524,"conditions":964,"interventions":965},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":967,"activeCount":98},[],{"intervention":531,"totalTrials":94,"cells":969},{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":984},{"trials":971,"activeCount":98},[],{"trials":973,"activeCount":98},[],{"trials":975,"activeCount":98},[],{"trials":977,"activeCount":98},[],{"trials":979,"activeCount":98},[980],{"nctId":519,"briefTitle":520,"status":140,"phases":981,"completion":522,"start":523,"enrollment":524,"conditions":982,"interventions":983},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":985,"activeCount":98},[],{"intervention":534,"totalTrials":94,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":1002},{"trials":989,"activeCount":98},[],{"trials":991,"activeCount":98},[],{"trials":993,"activeCount":98},[],{"trials":995,"activeCount":98},[],{"trials":997,"activeCount":98},[998],{"nctId":519,"briefTitle":520,"status":140,"phases":999,"completion":522,"start":523,"enrollment":524,"conditions":1000,"interventions":1001},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":1003,"activeCount":98},[],{"intervention":535,"totalTrials":94,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1020},{"trials":1007,"activeCount":98},[],{"trials":1009,"activeCount":98},[],{"trials":1011,"activeCount":98},[],{"trials":1013,"activeCount":98},[],{"trials":1015,"activeCount":98},[1016],{"nctId":519,"briefTitle":520,"status":140,"phases":1017,"completion":522,"start":523,"enrollment":524,"conditions":1018,"interventions":1019},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":1021,"activeCount":98},[],{"intervention":1023,"totalTrials":94,"cells":1024},"Nortriptyline-lithium",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1043},{"trials":1026,"activeCount":98},[],{"trials":1028,"activeCount":98},[],{"trials":1030,"activeCount":98},[],{"trials":1032,"activeCount":98},[],{"trials":1034,"activeCount":98},[1035],{"nctId":1036,"briefTitle":1037,"status":140,"phases":1038,"start":1039,"conditions":1040,"interventions":1041},"NCT00000375","Continuation Electroconvulsive Therapy Vs Medication to Prevent Relapses in Patients With Major Depressive Disorder",[89],"1997-02",[26],[1023,1042],"Continuation therapy",{"trials":1044,"activeCount":98},[],{"intervention":1042,"totalTrials":94,"cells":1046},{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1053,"PHASE4":1055,"NA":1061},{"trials":1048,"activeCount":98},[],{"trials":1050,"activeCount":98},[],{"trials":1052,"activeCount":98},[],{"trials":1054,"activeCount":98},[],{"trials":1056,"activeCount":98},[1057],{"nctId":1036,"briefTitle":1037,"status":140,"phases":1058,"start":1039,"conditions":1059,"interventions":1060},[89],[26],[1023,1042],{"trials":1062,"activeCount":98},[],{"intervention":627,"totalTrials":94,"cells":1064},{"EARLY_PHASE1":1065,"PHASE1":1067,"PHASE2":1069,"PHASE3":1071,"PHASE4":1073,"NA":1079},{"trials":1066,"activeCount":98},[],{"trials":1068,"activeCount":98},[],{"trials":1070,"activeCount":98},[],{"trials":1072,"activeCount":98},[],{"trials":1074,"activeCount":98},[1075],{"nctId":616,"briefTitle":617,"status":140,"phases":1076,"completion":619,"start":620,"enrollment":621,"conditions":1077,"interventions":1078},[89],[24],[624,625,626,551,627,628,629],{"trials":1080,"activeCount":98},[],{"intervention":629,"totalTrials":94,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1089,"PHASE4":1091,"NA":1097},{"trials":1084,"activeCount":98},[],{"trials":1086,"activeCount":98},[],{"trials":1088,"activeCount":98},[],{"trials":1090,"activeCount":98},[],{"trials":1092,"activeCount":98},[1093],{"nctId":616,"briefTitle":617,"status":140,"phases":1094,"completion":619,"start":620,"enrollment":621,"conditions":1095,"interventions":1096},[89],[24],[624,625,626,551,627,628,629],{"trials":1098,"activeCount":98},[],{"intervention":749,"totalTrials":94,"cells":1100},{"EARLY_PHASE1":1101,"PHASE1":1103,"PHASE2":1105,"PHASE3":1107,"PHASE4":1109,"NA":1115},{"trials":1102,"activeCount":98},[],{"trials":1104,"activeCount":98},[],{"trials":1106,"activeCount":98},[],{"trials":1108,"activeCount":98},[],{"trials":1110,"activeCount":98},[1111],{"nctId":739,"briefTitle":740,"status":140,"phases":1112,"primaryCompletion":742,"completion":730,"start":743,"enrollment":744,"conditions":1113,"interventions":1114},[89],[24],[604,747,714,748,749,750],{"trials":1116,"activeCount":98},[],{"intervention":750,"totalTrials":94,"cells":1118},{"EARLY_PHASE1":1119,"PHASE1":1121,"PHASE2":1123,"PHASE3":1125,"PHASE4":1127,"NA":1133},{"trials":1120,"activeCount":98},[],{"trials":1122,"activeCount":98},[],{"trials":1124,"activeCount":98},[],{"trials":1126,"activeCount":98},[],{"trials":1128,"activeCount":98},[1129],{"nctId":739,"briefTitle":740,"status":140,"phases":1130,"primaryCompletion":742,"completion":730,"start":743,"enrollment":744,"conditions":1131,"interventions":1132},[89],[24],[604,747,714,748,749,750],{"trials":1134,"activeCount":98},[],{"intervention":1136,"totalTrials":94,"cells":1137},"Minocycline",{"EARLY_PHASE1":1138,"PHASE1":1140,"PHASE2":1142,"PHASE3":1144,"PHASE4":1146,"NA":1160},{"trials":1139,"activeCount":98},[],{"trials":1141,"activeCount":98},[],{"trials":1143,"activeCount":98},[],{"trials":1145,"activeCount":98},[],{"trials":1147,"activeCount":98},[1148],{"nctId":1149,"briefTitle":1150,"status":140,"phases":1151,"primaryCompletion":1152,"completion":1153,"start":1154,"enrollment":1155,"conditions":1156,"interventions":1159},"NCT00409747","Minocycline to Treat Childhood Regressive Autism",[89],"2010-06","2011-04","2006-11",11,[1157,1136,1158],"Autism","Regressive Autism",[1136],{"trials":1161,"activeCount":98},[],{"intervention":1163,"totalTrials":94,"cells":1164},"Lovostatin",{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1171,"PHASE4":1173,"NA":1185},{"trials":1166,"activeCount":98},[],{"trials":1168,"activeCount":98},[],{"trials":1170,"activeCount":98},[],{"trials":1172,"activeCount":98},[],{"trials":1174,"activeCount":98},[1175],{"nctId":1176,"briefTitle":1177,"status":140,"phases":1178,"completion":1179,"start":1180,"enrollment":656,"conditions":1181,"interventions":1183},"NCT00046358","The Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer's Disease",[89],"2005-08","2002-09",[1182],"Alzheimer Disease",[1163,1184],"Ibuprofen",{"trials":1186,"activeCount":98},[],{"intervention":1184,"totalTrials":94,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1203},{"trials":1190,"activeCount":98},[],{"trials":1192,"activeCount":98},[],{"trials":1194,"activeCount":98},[],{"trials":1196,"activeCount":98},[],{"trials":1198,"activeCount":98},[1199],{"nctId":1176,"briefTitle":1177,"status":140,"phases":1200,"completion":1179,"start":1180,"enrollment":656,"conditions":1201,"interventions":1202},[89],[1182],[1163,1184],{"trials":1204,"activeCount":98},[],{"intervention":1206,"totalTrials":94,"cells":1207},"Lithium Carbonate",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1227},{"trials":1209,"activeCount":98},[],{"trials":1211,"activeCount":98},[],{"trials":1213,"activeCount":98},[],{"trials":1215,"activeCount":98},[],{"trials":1217,"activeCount":98},[1218],{"nctId":1219,"briefTitle":1220,"status":140,"phases":1221,"primaryCompletion":690,"completion":690,"start":1222,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT00667745","Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder",[89],"2008-04",283,[21],[1206,1226],"Optimized Treatment",{"trials":1228,"activeCount":98},[],{"intervention":1226,"totalTrials":94,"cells":1230},{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1245},{"trials":1232,"activeCount":98},[],{"trials":1234,"activeCount":98},[],{"trials":1236,"activeCount":98},[],{"trials":1238,"activeCount":98},[],{"trials":1240,"activeCount":98},[1241],{"nctId":1219,"briefTitle":1220,"status":140,"phases":1242,"primaryCompletion":690,"completion":690,"start":1222,"enrollment":1223,"conditions":1243,"interventions":1244},[89],[21],[1206,1226],{"trials":1246,"activeCount":98},[],{"intervention":1248,"totalTrials":94,"cells":1249},"Amoxicillin",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1256,"PHASE4":1258,"NA":1273},{"trials":1251,"activeCount":98},[],{"trials":1253,"activeCount":98},[],{"trials":1255,"activeCount":98},[],{"trials":1257,"activeCount":98},[],{"trials":1259,"activeCount":98},[1260],{"nctId":1261,"briefTitle":1262,"status":140,"phases":1263,"completion":1264,"start":1265,"enrollment":180,"conditions":1266,"interventions":1272},"NCT00001658","Amoxicillin for the Treatment of Pediatric Autoimmune Disorders Associated With Streptococcal Infections",[89],"2001-06","1997-07",[1267,1268,1269,1270,1271],"Autoimmune Disease","Mental Disorder","Obsessive Compulsive Disorder","Streptococcal Infection","Tic Disorder",[1248],{"trials":1274,"activeCount":98},[],{"intervention":1276,"totalTrials":94,"cells":1277},"SSRI + placebo",{"EARLY_PHASE1":1278,"PHASE1":1280,"PHASE2":1282,"PHASE3":1284,"PHASE4":1286,"NA":1297},{"trials":1279,"activeCount":98},[],{"trials":1281,"activeCount":98},[],{"trials":1283,"activeCount":98},[],{"trials":1285,"activeCount":98},[],{"trials":1287,"activeCount":98},[1288],{"nctId":1289,"briefTitle":1290,"status":140,"phases":1291,"primaryCompletion":742,"completion":742,"start":705,"enrollment":1292,"conditions":1293,"interventions":1294},"NCT00590863","Combining Medications to Enhance Depression Outcomes",[89],665,[26],[1276,1295,1296],"Escitalopram + Bupropion SR","Venlafaxine XR + Mirtazapine",{"trials":1298,"activeCount":98},[],{"intervention":1295,"totalTrials":94,"cells":1300},{"EARLY_PHASE1":1301,"PHASE1":1303,"PHASE2":1305,"PHASE3":1307,"PHASE4":1309,"NA":1315},{"trials":1302,"activeCount":98},[],{"trials":1304,"activeCount":98},[],{"trials":1306,"activeCount":98},[],{"trials":1308,"activeCount":98},[],{"trials":1310,"activeCount":98},[1311],{"nctId":1289,"briefTitle":1290,"status":140,"phases":1312,"primaryCompletion":742,"completion":742,"start":705,"enrollment":1292,"conditions":1313,"interventions":1314},[89],[26],[1276,1295,1296],{"trials":1316,"activeCount":98},[],{"intervention":1296,"totalTrials":94,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1325,"PHASE4":1327,"NA":1333},{"trials":1320,"activeCount":98},[],{"trials":1322,"activeCount":98},[],{"trials":1324,"activeCount":98},[],{"trials":1326,"activeCount":98},[],{"trials":1328,"activeCount":98},[1329],{"nctId":1289,"briefTitle":1290,"status":140,"phases":1330,"primaryCompletion":742,"completion":742,"start":705,"enrollment":1292,"conditions":1331,"interventions":1332},[89],[26],[1276,1295,1296],{"trials":1334,"activeCount":98},[],{"intervention":1336,"totalTrials":94,"cells":1337},"Memantine HCL",{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1355,"NA":1357},{"trials":1339,"activeCount":98},[],{"trials":1341,"activeCount":98},[],{"trials":1343,"activeCount":98},[],{"trials":1345,"activeCount":98},[1346],{"nctId":1347,"briefTitle":1348,"status":140,"phases":1349,"completion":1350,"start":1351,"enrollment":1352,"conditions":1353,"interventions":1354},"NCT00040261","Clinical Trial of Memantine for Major Depression",[88],"2005-03","2002-06",112,[18],[1336],{"trials":1356,"activeCount":98},[],{"trials":1358,"activeCount":98},[],{"intervention":1360,"totalTrials":94,"cells":1361},"Gamunex Intravenous Immunoglobulin",{"EARLY_PHASE1":1362,"PHASE1":1364,"PHASE2":1366,"PHASE3":1368,"PHASE4":1383,"NA":1385},{"trials":1363,"activeCount":98},[],{"trials":1365,"activeCount":98},[],{"trials":1367,"activeCount":98},[],{"trials":1369,"activeCount":98},[1370],{"nctId":1371,"briefTitle":1372,"status":140,"phases":1373,"primaryCompletion":1374,"completion":1375,"start":1376,"enrollment":1377,"conditions":1378,"interventions":1382},"NCT01281969","Intravenous Immunoglobulin for PANDAS",[88],"2015-12","2018-08-13","2011-01",48,[1379,1380,672,1267,1381],"Obsessive-Compulsive Disorder","Children","PANDAS",[1360],{"trials":1384,"activeCount":98},[],{"trials":1386,"activeCount":98},[],{"intervention":1388,"totalTrials":94,"cells":1389},"Intravenous immunoglobulin",{"EARLY_PHASE1":1390,"PHASE1":1392,"PHASE2":1394,"PHASE3":1396,"PHASE4":1408,"NA":1410},{"trials":1391,"activeCount":98},[],{"trials":1393,"activeCount":98},[],{"trials":1395,"activeCount":98},[],{"trials":1397,"activeCount":98},[1398],{"nctId":1399,"briefTitle":1400,"status":140,"phases":1401,"completion":1402,"start":1403,"enrollment":9,"conditions":1404,"interventions":1407},"NCT00001768","Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)",[88],"2000-06","1997-10",[1405,1406,24],"Autoimmune Diseases","Mental Disorders Diagnosed in Childhood",[1388],{"trials":1409,"activeCount":98},[],{"trials":1411,"activeCount":98},[],{"intervention":1413,"totalTrials":121,"cells":1414},"Riluzole",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1419,"PHASE3":1460,"PHASE4":1462,"NA":1464},{"trials":1416,"activeCount":98},[],{"trials":1418,"activeCount":98},[],{"trials":1420,"activeCount":98},[1421,1432,1442,1451],{"nctId":1422,"briefTitle":1423,"status":150,"phases":1424,"primaryCompletion":1425,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1431},"NCT00805493","Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder",[87],"2012-06","2008-11",6,[21,31,1429,1430],"Bipolar Affective Disorder","Bipolar Depression",[1413],{"nctId":1433,"briefTitle":1434,"status":140,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1179,"enrollment":846,"conditions":1437,"interventions":1441},"NCT00251303","Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders",[87],"2012-02",[1379,1438,1157,1439,1440],"Autism Spectrum Disorder","Asperger Disorder","Developmental Disorder",[1413],{"nctId":1443,"briefTitle":1444,"status":150,"phases":1445,"primaryCompletion":1446,"completion":1446,"start":1447,"enrollment":1448,"conditions":1449,"interventions":1450},"NCT00054704","Riluzole to Treat Depression in Bipolar Disorder",[87],"2014-12","2003-02",19,[21],[1413],{"nctId":1452,"briefTitle":1453,"status":140,"phases":1454,"completion":1455,"start":1456,"enrollment":292,"conditions":1457,"interventions":1458},"NCT00026052","Riluzole to Treat Major Depression",[87],"2003-04","2001-11",[18],[1459],"riluzole",{"trials":1461,"activeCount":98},[],{"trials":1463,"activeCount":98},[],{"trials":1465,"activeCount":98},[],{"intervention":1467,"totalTrials":170,"cells":1468},"Peptide T",{"EARLY_PHASE1":1469,"PHASE1":1471,"PHASE2":1489,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1470,"activeCount":98},[],{"trials":1472,"activeCount":98},[1473,1482],{"nctId":1474,"briefTitle":1475,"status":140,"phases":1476,"primaryCompletion":1477,"start":1478,"enrollment":180,"conditions":1479,"interventions":1481},"NCT00000391","A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients.",[86],"1990-01","1988-01",[1480],"HIV Infections",[1467],{"nctId":1483,"briefTitle":1484,"status":140,"phases":1485,"primaryCompletion":1477,"start":1478,"enrollment":1427,"conditions":1486,"interventions":1488},"NCT00000393","A Phase I Trial of Peptide T: Efficacy for the Neuropsychiatric Complications of Acquired Immunodeficiency Syndrome (AIDS).",[86],[1480,1487],"Cognition Disorders",[1467],{"trials":1490,"activeCount":98},[1491],{"nctId":1492,"briefTitle":1493,"status":140,"phases":1494,"primaryCompletion":1495,"completion":1495,"start":1477,"enrollment":732,"conditions":1496,"interventions":1497},"NCT00000392","Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.",[87],"1996-08",[1480,1487],[1467],{"trials":1499,"activeCount":98},[],{"trials":1501,"activeCount":98},[],{"trials":1503,"activeCount":98},[],{"intervention":1505,"totalTrials":170,"cells":1506},"Progesterone",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1523,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1508,"activeCount":98},[],{"trials":1510,"activeCount":98},[1511],{"nctId":1512,"briefTitle":1513,"status":140,"phases":1514,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":226,"conditions":1517,"interventions":1520},"NCT00001259","A Treatment Study for Premenstrual Syndrome (PMS)",[86],"2020-02-06","1992-08-11",[1518,1519],"Premenstrual Syndrome","Menstruation Disturbances",[1521,1522,1505],"Leuprolide","Estradiol Patches",{"trials":1524,"activeCount":98},[1525,1537],{"nctId":1526,"briefTitle":1527,"status":140,"phases":1528,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":1532,"interventions":1534},"NCT00001481","The Role of Hormones in Postpartum Mood Disorders",[87],"2024-10-25","1996-04-26",74,[1533],"Postpartum Depression",[1535,1505,1536],"Estradiol","leuprolide acetate",{"nctId":1538,"briefTitle":1539,"status":140,"phases":1540,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1545},"NCT00001322","The Effects of Reproductive Hormones on Mood and Behavior",[86,87],"2020-03-03","1994-06-09",100,[112],[1546,1535,1505],"Leuprolide Acetate 3.75",{"trials":1548,"activeCount":98},[],{"trials":1550,"activeCount":98},[],{"trials":1552,"activeCount":98},[],{"intervention":1535,"totalTrials":170,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1580,"PHASE4":1582,"NA":1584},{"trials":1556,"activeCount":98},[],{"trials":1558,"activeCount":98},[],{"trials":1560,"activeCount":98},[1561,1565,1576],{"nctId":1526,"briefTitle":1527,"status":140,"phases":1562,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":1563,"interventions":1564},[87],[1533],[1535,1505,1536],{"nctId":1566,"briefTitle":1567,"status":140,"phases":1568,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":1531,"conditions":1571,"interventions":1573},"NCT03689543","Estrogen Receptor Beta and Mood",[87],"2024-09-09","2019-05-23",[1572],"Perimenopause-Related Depression",[1535,1574,1575],"ER Beta Agonist","Provera",{"nctId":1538,"briefTitle":1539,"status":140,"phases":1577,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":1543,"conditions":1578,"interventions":1579},[86,87],[112],[1546,1535,1505],{"trials":1581,"activeCount":98},[],{"trials":1583,"activeCount":98},[],{"trials":1585,"activeCount":98},[],{"intervention":695,"totalTrials":231,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1606,"PHASE4":1608,"NA":1610},{"trials":1589,"activeCount":98},[],{"trials":1591,"activeCount":98},[],{"trials":1593,"activeCount":98},[1594,1598],{"nctId":687,"briefTitle":688,"status":140,"phases":1595,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":1596,"interventions":1597},[87],[397],[695,678],{"nctId":1599,"briefTitle":1600,"status":140,"phases":1601,"completion":1602,"start":845,"enrollment":1603,"conditions":1604,"interventions":1605},"NCT00025792","Clinical Trial of Pramipexole in Bipolar Depression",[87],"2005-11",200,[21],[695],{"trials":1607,"activeCount":98},[],{"trials":1609,"activeCount":98},[],{"trials":1611,"activeCount":98},[],{"intervention":246,"totalTrials":231,"cells":1613},{"EARLY_PHASE1":1614,"PHASE1":1616,"PHASE2":1622,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1615,"activeCount":98},[],{"trials":1617,"activeCount":98},[1618],{"nctId":287,"briefTitle":288,"status":150,"phases":1619,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":1620,"interventions":1621},[86],[294,295,296,112],[83,246,298],{"trials":1623,"activeCount":98},[1624],{"nctId":235,"briefTitle":236,"status":150,"phases":1625,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":1626,"interventions":1627},[87],[243],[83,59,245,246],{"trials":1629,"activeCount":98},[],{"trials":1631,"activeCount":98},[],{"trials":1633,"activeCount":98},[],{"intervention":1635,"totalTrials":94,"cells":1636},"SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain",{"EARLY_PHASE1":1637,"PHASE1":1639,"PHASE2":1641,"PHASE3":1649,"PHASE4":1651,"NA":1653},{"trials":1638,"activeCount":98},[],{"trials":1640,"activeCount":98},[],{"trials":1642,"activeCount":98},[1643],{"nctId":1644,"briefTitle":1645,"status":140,"phases":1646,"completion":844,"start":1447,"enrollment":1543,"conditions":1647,"interventions":1648},"NCT00061789","Imaging of Brain Receptors in Healthy Volunteers and in Patients With Schizophrenia",[87],[24],[1635],{"trials":1650,"activeCount":98},[],{"trials":1652,"activeCount":98},[],{"trials":1654,"activeCount":98},[],{"intervention":1656,"totalTrials":94,"cells":1657},"Donepezil",{"EARLY_PHASE1":1658,"PHASE1":1660,"PHASE2":1662,"PHASE3":1672,"PHASE4":1674,"NA":1676},{"trials":1659,"activeCount":98},[],{"trials":1661,"activeCount":98},[],{"trials":1663,"activeCount":98},[1664],{"nctId":1665,"briefTitle":1666,"status":150,"phases":1667,"primaryCompletion":1374,"completion":1374,"start":1668,"enrollment":563,"conditions":1669,"interventions":1671},"NCT01887132","A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism",[87],"2013-06",[1670],"Autism Spectrum Disorders",[1656],{"trials":1673,"activeCount":98},[],{"trials":1675,"activeCount":98},[],{"trials":1677,"activeCount":98},[],{"intervention":1679,"totalTrials":94,"cells":1680},"Scopolamine Nasal Spray",{"EARLY_PHASE1":1681,"PHASE1":1683,"PHASE2":1685,"PHASE3":1697,"PHASE4":1699,"NA":1701},{"trials":1682,"activeCount":98},[],{"trials":1684,"activeCount":98},[],{"trials":1686,"activeCount":98},[1687],{"nctId":1688,"briefTitle":1689,"status":150,"phases":1690,"primaryCompletion":1691,"completion":1691,"start":1692,"enrollment":1693,"conditions":1694,"interventions":1696},"NCT00055575","Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies",[87],"2015-02-02","2003-02-27",197,[34,15,1695,1430],"Unipolar Depression",[1679],{"trials":1698,"activeCount":98},[],{"trials":1700,"activeCount":98},[],{"trials":1702,"activeCount":98},[],{"intervention":1704,"totalTrials":94,"cells":1705},"Org 24448",{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1707,"activeCount":98},[],{"trials":1709,"activeCount":98},[],{"trials":1711,"activeCount":98},[1712],{"nctId":1713,"briefTitle":1714,"status":150,"phases":1715,"primaryCompletion":1716,"completion":1716,"start":1717,"enrollment":1718,"conditions":1719,"interventions":1720},"NCT00113022","Org 24448 to Treat Major Depression",[87],"2007-02","2005-05",9,[18],[1704],{"trials":1722,"activeCount":98},[],{"trials":1724,"activeCount":98},[],{"trials":1726,"activeCount":98},[],{"intervention":1728,"totalTrials":94,"cells":1729},"levetiracetam",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1731,"activeCount":98},[],{"trials":1733,"activeCount":98},[],{"trials":1735,"activeCount":98},[1736],{"nctId":1737,"briefTitle":1738,"status":140,"phases":1739,"completion":1455,"start":1740,"enrollment":180,"conditions":1741,"interventions":1742},"NCT00015769","Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness",[87],"2001-04",[21],[1728],{"trials":1744,"activeCount":98},[],{"trials":1746,"activeCount":98},[],{"trials":1748,"activeCount":98},[],{"intervention":1750,"totalTrials":94,"cells":1751},"Felbamate",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1767,"PHASE4":1769,"NA":1771},{"trials":1753,"activeCount":98},[],{"trials":1755,"activeCount":98},[],{"trials":1757,"activeCount":98},[1758],{"nctId":1759,"briefTitle":1760,"status":140,"phases":1761,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1766},"NCT00034229","Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression",[87],"2006-03","2002-04",52,[21],[1750],{"trials":1768,"activeCount":98},[],{"trials":1770,"activeCount":98},[],{"trials":1772,"activeCount":98},[],{"intervention":1774,"totalTrials":94,"cells":1775},"Atomoxetine",{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1780,"PHASE3":1791,"PHASE4":1793,"NA":1795},{"trials":1777,"activeCount":98},[],{"trials":1779,"activeCount":98},[],{"trials":1781,"activeCount":98},[1782],{"nctId":1783,"briefTitle":1784,"status":150,"phases":1785,"primaryCompletion":1786,"completion":1786,"start":1787,"enrollment":1155,"conditions":1788,"interventions":1790},"NCT00548327","The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype",[87],"2011-11","2007-10",[24,1789,1487],"Memory Disorders",[1774],{"trials":1792,"activeCount":98},[],{"trials":1794,"activeCount":98},[],{"trials":1796,"activeCount":98},[],{"intervention":1798,"totalTrials":94,"cells":1799},"Divalproex Sodium",{"EARLY_PHASE1":1800,"PHASE1":1802,"PHASE2":1804,"PHASE3":1815,"PHASE4":1817,"NA":1819},{"trials":1801,"activeCount":98},[],{"trials":1803,"activeCount":98},[],{"trials":1805,"activeCount":98},[1806],{"nctId":1807,"briefTitle":1808,"status":1809,"phases":1810,"primaryCompletion":1811,"completion":1811,"start":1812,"enrollment":98,"conditions":1813,"interventions":1814},"NCT01170325","A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG","WITHDRAWN",[87],"2011-01-28","2010-06-30",[1157,1670],[1798],{"trials":1816,"activeCount":98},[],{"trials":1818,"activeCount":98},[],{"trials":1820,"activeCount":98},[],{"intervention":1822,"totalTrials":94,"cells":1823},"Ethyl Eicosapentaenoic Acid",{"EARLY_PHASE1":1824,"PHASE1":1826,"PHASE2":1828,"PHASE3":1841,"PHASE4":1843,"NA":1845},{"trials":1825,"activeCount":98},[],{"trials":1827,"activeCount":98},[],{"trials":1829,"activeCount":98},[1830],{"nctId":1831,"briefTitle":1832,"status":140,"phases":1833,"completion":1834,"start":1835,"enrollment":1836,"conditions":1837,"interventions":1839},"NCT00001146","Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial",[87],"2002-08","1999-10",240,[21,1838,29],"Involutional Depression",[1822,1840],"OmegaBrite",{"trials":1842,"activeCount":98},[],{"trials":1844,"activeCount":98},[],{"trials":1846,"activeCount":98},[],{"intervention":1840,"totalTrials":94,"cells":1848},{"EARLY_PHASE1":1849,"PHASE1":1851,"PHASE2":1853,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1850,"activeCount":98},[],{"trials":1852,"activeCount":98},[],{"trials":1854,"activeCount":98},[1855],{"nctId":1831,"briefTitle":1832,"status":140,"phases":1856,"completion":1834,"start":1835,"enrollment":1836,"conditions":1857,"interventions":1858},[87],[21,1838,29],[1822,1840],{"trials":1860,"activeCount":98},[],{"trials":1862,"activeCount":98},[],{"trials":1864,"activeCount":98},[],{"intervention":1866,"totalTrials":94,"cells":1867},"Add-on citalopram following optimized methylphenidate",{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1872,"PHASE3":1887,"PHASE4":1889,"NA":1891},{"trials":1869,"activeCount":98},[],{"trials":1871,"activeCount":98},[],{"trials":1873,"activeCount":98},[1874],{"nctId":1875,"briefTitle":1876,"status":140,"phases":1877,"primaryCompletion":1878,"completion":1878,"start":1879,"enrollment":1880,"conditions":1881,"interventions":1885},"NCT00794040","A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation",[87],"2018-02-01","2008-11-17",103,[29,1882,1883,1884],"Mental Disorder Diagnosed in Childhood","Attention Deficit and Disruptive Behavior Disorder","Attention Deficit Hyperactivity Disorder",[1866,1886],"Add-on placebo following optimized methylphenidate",{"trials":1888,"activeCount":98},[],{"trials":1890,"activeCount":98},[],{"trials":1892,"activeCount":98},[],{"intervention":1886,"totalTrials":94,"cells":1894},{"EARLY_PHASE1":1895,"PHASE1":1897,"PHASE2":1899,"PHASE3":1905,"PHASE4":1907,"NA":1909},{"trials":1896,"activeCount":98},[],{"trials":1898,"activeCount":98},[],{"trials":1900,"activeCount":98},[1901],{"nctId":1875,"briefTitle":1876,"status":140,"phases":1902,"primaryCompletion":1878,"completion":1878,"start":1879,"enrollment":1880,"conditions":1903,"interventions":1904},[87],[29,1882,1883,1884],[1866,1886],{"trials":1906,"activeCount":98},[],{"trials":1908,"activeCount":98},[],{"trials":1910,"activeCount":98},[],{"intervention":1912,"totalTrials":94,"cells":1913},"Glycine",{"EARLY_PHASE1":1914,"PHASE1":1916,"PHASE2":1918,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1915,"activeCount":98},[],{"trials":1917,"activeCount":98},[],{"trials":1919,"activeCount":98},[1920],{"nctId":1921,"briefTitle":1922,"status":140,"phases":1923,"completion":576,"start":1924,"enrollment":9,"conditions":1925,"interventions":1927},"NCT00005658","Glycine to Treat Psychotic Disorders in Children",[87],"2000-05",[602,1926,24],"Schizoaffecitve Disorder",[1912],{"trials":1929,"activeCount":98},[],{"trials":1931,"activeCount":98},[],{"trials":1933,"activeCount":98},[],{"intervention":1935,"totalTrials":94,"cells":1936},"Mifepristone",{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1941,"PHASE3":1952,"PHASE4":1954,"NA":1956},{"trials":1938,"activeCount":98},[],{"trials":1940,"activeCount":98},[],{"trials":1942,"activeCount":98},[1943],{"nctId":1944,"briefTitle":1945,"status":140,"phases":1946,"completion":1947,"start":1948,"enrollment":1949,"conditions":1950,"interventions":1951},"NCT00043654","Clinical Trial of Mifepristone for Bipolar Depression",[87],"2007-06-25","2002-08-07",110,[21],[1935],{"trials":1953,"activeCount":98},[],{"trials":1955,"activeCount":98},[],{"trials":1957,"activeCount":98},[],{"intervention":1959,"totalTrials":94,"cells":1960},"Donepezil hydrochloride",{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1965,"PHASE3":1975,"PHASE4":1977,"NA":1979},{"trials":1962,"activeCount":98},[],{"trials":1964,"activeCount":98},[],{"trials":1966,"activeCount":98},[1967],{"nctId":1968,"briefTitle":1969,"status":140,"phases":1970,"primaryCompletion":1376,"completion":1376,"start":597,"enrollment":1971,"conditions":1972,"interventions":1974},"NCT00695136","The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism",[86,87],17,[1157,1973],"Cognition Disorder",[1959],{"trials":1976,"activeCount":98},[],{"trials":1978,"activeCount":98},[],{"trials":1980,"activeCount":98},[],{"intervention":1982,"totalTrials":94,"cells":1983},"[11C]PBR28 and Positron Emission Tomography",{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1985,"activeCount":98},[],{"trials":1987,"activeCount":98},[],{"trials":1989,"activeCount":98},[1990],{"nctId":1991,"briefTitle":1992,"status":140,"phases":1993,"primaryCompletion":1994,"completion":1994,"start":1995,"enrollment":1764,"conditions":1996,"interventions":1998},"NCT01547780","Translocator Protein and Inflammation After Traumatic Brain Injury",[86,87],"2017-09-28","2012-01-20",[1997,15],"Traumatic Brain Injury (TBI)",[1982],{"trials":2000,"activeCount":98},[],{"trials":2002,"activeCount":98},[],{"trials":2004,"activeCount":98},[],{"intervention":2006,"totalTrials":94,"cells":2007},"AV 101",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2009,"activeCount":98},[],{"trials":2011,"activeCount":98},[],{"trials":2013,"activeCount":98},[2014],{"nctId":2015,"briefTitle":2016,"status":140,"phases":2017,"primaryCompletion":2018,"completion":2019,"start":2020,"enrollment":2021,"conditions":2022,"interventions":2023},"NCT02484456","Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder",[87],"2019-02-21","2019-12-03","2015-10-14",22,[397],[2006],{"trials":2025,"activeCount":98},[],{"trials":2027,"activeCount":98},[],{"trials":2029,"activeCount":98},[],{"intervention":2031,"totalTrials":94,"cells":2032},"DMSA",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2048,"PHASE4":2050,"NA":2052},{"trials":2034,"activeCount":98},[],{"trials":2036,"activeCount":98},[],{"trials":2038,"activeCount":98},[2039],{"nctId":2040,"briefTitle":2041,"status":1809,"phases":2042,"completion":2043,"start":522,"enrollment":98,"conditions":2044,"interventions":2047},"NCT00376194","Mercury Chelation to Treat Autism",[87],"2007-03",[1157,2045,2046],"Asperger's Disorder","Child Development Disorders, Pervasive",[2031],{"trials":2049,"activeCount":98},[],{"trials":2051,"activeCount":98},[],{"trials":2053,"activeCount":98},[],{"intervention":1536,"totalTrials":94,"cells":2055},{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2066,"PHASE4":2068,"NA":2070},{"trials":2057,"activeCount":98},[],{"trials":2059,"activeCount":98},[],{"trials":2061,"activeCount":98},[2062],{"nctId":1526,"briefTitle":1527,"status":140,"phases":2063,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":1531,"conditions":2064,"interventions":2065},[87],[1533],[1535,1505,1536],{"trials":2067,"activeCount":98},[],{"trials":2069,"activeCount":98},[],{"trials":2071,"activeCount":98},[],{"intervention":2073,"totalTrials":94,"cells":2074},"Penicillin or Placebo",{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2089,"PHASE4":2091,"NA":2093},{"trials":2076,"activeCount":98},[],{"trials":2078,"activeCount":98},[],{"trials":2080,"activeCount":98},[2081],{"nctId":2082,"briefTitle":2083,"status":140,"phases":2084,"completion":2085,"start":2086,"enrollment":264,"conditions":2087,"interventions":2088},"NCT00001359","Preventive Measures for Childhood-Onset Obsessive-Compulsive Disorder and Tic Disorders (PANDAS Subgroup)",[87],"2006-01","1993-04",[1882,1269,1270,1271],[2073],{"trials":2090,"activeCount":98},[],{"trials":2092,"activeCount":98},[],{"trials":2094,"activeCount":98},[],{"intervention":2096,"totalTrials":94,"cells":2097},"Intranasal Oxytocin",{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2113,"PHASE4":2115,"NA":2117},{"trials":2099,"activeCount":98},[],{"trials":2101,"activeCount":98},[],{"trials":2103,"activeCount":98},[2104],{"nctId":2105,"briefTitle":2106,"status":150,"phases":2107,"primaryCompletion":2108,"start":2109,"enrollment":27,"conditions":2110,"interventions":2112},"NCT01712646","Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia",[86,87],"2016-06-20","2012-10-05",[2111,24],"Childhood Onset Psychotic Disorders",[2096],{"trials":2114,"activeCount":98},[],{"trials":2116,"activeCount":98},[],{"trials":2118,"activeCount":98},[],{"intervention":2120,"totalTrials":94,"cells":2121},"(18F)fallypride",{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2137,"PHASE4":2139,"NA":2141},{"trials":2123,"activeCount":98},[],{"trials":2125,"activeCount":98},[],{"trials":2127,"activeCount":98},[2128],{"nctId":2129,"briefTitle":2130,"status":140,"phases":2131,"completion":2132,"start":2133,"enrollment":2134,"conditions":2135,"interventions":2136},"NCT00062946","PET Imaging of Dopamine in Healthy Study Participants",[87],"2007-08-15","2003-06-17",45,[15],[2120],{"trials":2138,"activeCount":98},[],{"trials":2140,"activeCount":98},[],{"trials":2142,"activeCount":98},[],{"intervention":2144,"totalTrials":94,"cells":2145},"Whole Body PET Baseline with 11C Rolipram",{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2163,"PHASE4":2165,"NA":2167},{"trials":2147,"activeCount":98},[],{"trials":2149,"activeCount":98},[],{"trials":2151,"activeCount":98},[2152],{"nctId":2153,"briefTitle":2154,"status":140,"phases":2155,"primaryCompletion":2156,"completion":2157,"start":2158,"enrollment":11,"conditions":2159,"interventions":2161},"NCT02743377","PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome",[86,87],"2019-10-23","2020-05-19","2018-04-04",[2160],"Nervous System Disease",[2144,2162],"Whole Body PET Blocked with Roflumilast",{"trials":2164,"activeCount":98},[],{"trials":2166,"activeCount":98},[],{"trials":2168,"activeCount":98},[],{"intervention":2162,"totalTrials":94,"cells":2170},{"EARLY_PHASE1":2171,"PHASE1":2173,"PHASE2":2175,"PHASE3":2181,"PHASE4":2183,"NA":2185},{"trials":2172,"activeCount":98},[],{"trials":2174,"activeCount":98},[],{"trials":2176,"activeCount":98},[2177],{"nctId":2153,"briefTitle":2154,"status":140,"phases":2178,"primaryCompletion":2156,"completion":2157,"start":2158,"enrollment":11,"conditions":2179,"interventions":2180},[86,87],[2160],[2144,2162],{"trials":2182,"activeCount":98},[],{"trials":2184,"activeCount":98},[],{"trials":2186,"activeCount":98},[],{"intervention":2188,"totalTrials":94,"cells":2189},"Scopolamine",{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2204,"PHASE4":2206,"NA":2208},{"trials":2191,"activeCount":98},[],{"trials":2193,"activeCount":98},[],{"trials":2195,"activeCount":98},[2196],{"nctId":2197,"briefTitle":2198,"status":150,"phases":2199,"primaryCompletion":2200,"completion":2200,"start":2201,"enrollment":1971,"conditions":2202,"interventions":2203},"NCT00369915","The Antidepressant Efficacy of the Anticholinergic Scopolamine",[87],"2013-01","2006-08",[1695,1430],[2188,2188],{"trials":2205,"activeCount":98},[],{"trials":2207,"activeCount":98},[],{"trials":2209,"activeCount":98},[],{"intervention":2211,"totalTrials":94,"cells":2212},"17beta Estradiol",{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2217,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2214,"activeCount":98},[],{"trials":2216,"activeCount":98},[],{"trials":2218,"activeCount":98},[2219],{"nctId":2220,"briefTitle":2221,"status":150,"phases":2222,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":2225,"conditions":2226,"interventions":2227},"NCT00059228","Clinical Trial of Estrogen for Postpartum Depression",[87],"2016-11-15","2003-04-17",12,[1533,18],[2211,2228],"Placebos",{"trials":2230,"activeCount":98},[],{"trials":2232,"activeCount":98},[],{"trials":2234,"activeCount":98},[],{"intervention":2228,"totalTrials":94,"cells":2236},{"EARLY_PHASE1":2237,"PHASE1":2239,"PHASE2":2241,"PHASE3":2247,"PHASE4":2249,"NA":2251},{"trials":2238,"activeCount":98},[],{"trials":2240,"activeCount":98},[],{"trials":2242,"activeCount":98},[2243],{"nctId":2220,"briefTitle":2221,"status":150,"phases":2244,"primaryCompletion":2223,"completion":2223,"start":2224,"enrollment":2225,"conditions":2245,"interventions":2246},[87],[1533,18],[2211,2228],{"trials":2248,"activeCount":98},[],{"trials":2250,"activeCount":98},[],{"trials":2252,"activeCount":98},[],{"intervention":2254,"totalTrials":94,"cells":2255},"TS-161",{"EARLY_PHASE1":2256,"PHASE1":2258,"PHASE2":2260,"PHASE3":2271,"PHASE4":2273,"NA":2275},{"trials":2257,"activeCount":98},[],{"trials":2259,"activeCount":98},[],{"trials":2261,"activeCount":98},[2262],{"nctId":2263,"briefTitle":2264,"status":150,"phases":2265,"primaryCompletion":2266,"completion":2266,"start":2267,"enrollment":1155,"conditions":2268,"interventions":2270},"NCT04821271","Antidepressant Effects of TS-161 in Treatment-Resistant Depression",[87],"2024-05-23","2021-06-10",[26,2269,18],"Treatment-Resistant Depression",[2254],{"trials":2272,"activeCount":98},[],{"trials":2274,"activeCount":98},[],{"trials":2276,"activeCount":98},[],{"intervention":2278,"totalTrials":94,"cells":2279},"Yohimbine hydrochloride",{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2294,"PHASE4":2296,"NA":2298},{"trials":2281,"activeCount":98},[],{"trials":2283,"activeCount":98},[],{"trials":2285,"activeCount":98},[2286],{"nctId":2287,"briefTitle":2288,"status":140,"phases":2289,"primaryCompletion":2290,"completion":2290,"start":142,"enrollment":1155,"conditions":2291,"interventions":2293},"NCT00078715","Rapid Antidepressant Effects of Yohimbine in Major Depression",[87],"2009-08",[2292,339],"Depression, Involutional",[2278],{"trials":2295,"activeCount":98},[],{"trials":2297,"activeCount":98},[],{"trials":2299,"activeCount":98},[],{"intervention":2301,"totalTrials":94,"cells":2302},"Diazoxide",{"EARLY_PHASE1":2303,"PHASE1":2305,"PHASE2":2307,"PHASE3":2317,"PHASE4":2319,"NA":2321},{"trials":2304,"activeCount":98},[],{"trials":2306,"activeCount":98},[],{"trials":2308,"activeCount":98},[2309],{"nctId":2310,"briefTitle":2311,"status":150,"phases":2312,"primaryCompletion":2313,"completion":2313,"start":2314,"enrollment":9,"conditions":2315,"interventions":2316},"NCT02049385","Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?",[86,87],"2016-07-21","2014-01-03",[18],[2301],{"trials":2318,"activeCount":98},[],{"trials":2320,"activeCount":98},[],{"trials":2322,"activeCount":98},[],{"intervention":1574,"totalTrials":94,"cells":2324},{"EARLY_PHASE1":2325,"PHASE1":2327,"PHASE2":2329,"PHASE3":2335,"PHASE4":2337,"NA":2339},{"trials":2326,"activeCount":98},[],{"trials":2328,"activeCount":98},[],{"trials":2330,"activeCount":98},[2331],{"nctId":1566,"briefTitle":1567,"status":140,"phases":2332,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":1531,"conditions":2333,"interventions":2334},[87],[1572],[1535,1574,1575],{"trials":2336,"activeCount":98},[],{"trials":2338,"activeCount":98},[],{"trials":2340,"activeCount":98},[],{"intervention":1575,"totalTrials":94,"cells":2342},{"EARLY_PHASE1":2343,"PHASE1":2345,"PHASE2":2347,"PHASE3":2353,"PHASE4":2355,"NA":2357},{"trials":2344,"activeCount":98},[],{"trials":2346,"activeCount":98},[],{"trials":2348,"activeCount":98},[2349],{"nctId":1566,"briefTitle":1567,"status":140,"phases":2350,"primaryCompletion":1569,"completion":1569,"start":1570,"enrollment":1531,"conditions":2351,"interventions":2352},[87],[1572],[1535,1574,1575],{"trials":2354,"activeCount":98},[],{"trials":2356,"activeCount":98},[],{"trials":2358,"activeCount":98},[],{"intervention":2360,"totalTrials":94,"cells":2361},"Coenzyme Q10",{"EARLY_PHASE1":2362,"PHASE1":2364,"PHASE2":2366,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2363,"activeCount":98},[],{"trials":2365,"activeCount":98},[],{"trials":2367,"activeCount":98},[2368],{"nctId":2369,"briefTitle":2370,"status":1809,"phases":2371,"primaryCompletion":2372,"start":2373,"enrollment":98,"conditions":2374,"interventions":2375},"NCT00327756","Mitochondrial Dysfunction in the Pathophysiology and Treatment of Bipolar Disorder",[87],"2009-05","2006-05",[1429,18],[2360],{"trials":2377,"activeCount":98},[],{"trials":2379,"activeCount":98},[],{"trials":2381,"activeCount":98},[],{"intervention":2383,"totalTrials":94,"cells":2384},"[C-11]T-1650",{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2389,"PHASE3":2400,"PHASE4":2402,"NA":2404},{"trials":2386,"activeCount":98},[],{"trials":2388,"activeCount":98},[],{"trials":2390,"activeCount":98},[2391],{"nctId":2392,"briefTitle":2393,"status":140,"phases":2394,"primaryCompletion":2395,"completion":2395,"start":2396,"enrollment":170,"conditions":2397,"interventions":2398},"NCT03861000","Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)",[86,87],"2020-02-11","2019-03-12",[18],[2383,2399],"BPN14770",{"trials":2401,"activeCount":98},[],{"trials":2403,"activeCount":98},[],{"trials":2405,"activeCount":98},[],{"intervention":2399,"totalTrials":94,"cells":2407},{"EARLY_PHASE1":2408,"PHASE1":2410,"PHASE2":2412,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2409,"activeCount":98},[],{"trials":2411,"activeCount":98},[],{"trials":2413,"activeCount":98},[2414],{"nctId":2392,"briefTitle":2393,"status":140,"phases":2415,"primaryCompletion":2395,"completion":2395,"start":2396,"enrollment":170,"conditions":2416,"interventions":2417},[86,87],[18],[2383,2399],{"trials":2419,"activeCount":98},[],{"trials":2421,"activeCount":98},[],{"trials":2423,"activeCount":98},[],{"intervention":2425,"totalTrials":94,"cells":2426},"Ceftriaxone",{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2441,"PHASE4":2443,"NA":2445},{"trials":2428,"activeCount":98},[],{"trials":2430,"activeCount":98},[],{"trials":2432,"activeCount":98},[2433],{"nctId":2434,"briefTitle":2435,"status":1809,"phases":2436,"primaryCompletion":2437,"completion":2437,"start":2438,"enrollment":98,"conditions":2439,"interventions":2440},"NCT00512616","A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder",[87],"2009-09-15","2007-08-01",[21],[2425],{"trials":2442,"activeCount":98},[],{"trials":2444,"activeCount":98},[],{"trials":2446,"activeCount":98},[],{"intervention":2448,"totalTrials":94,"cells":2449},"Methylphenidate Hydrochloride",{"EARLY_PHASE1":2450,"PHASE1":2452,"PHASE2":2454,"PHASE3":2466,"PHASE4":2468,"NA":2470},{"trials":2451,"activeCount":98},[],{"trials":2453,"activeCount":98},[],{"trials":2455,"activeCount":98},[2456],{"nctId":2457,"briefTitle":2458,"status":1809,"phases":2459,"primaryCompletion":2460,"completion":2460,"start":2461,"enrollment":98,"conditions":2462,"interventions":2465},"NCT02247986","Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder",[86,87],"2015-05-18","2014-09-04",[2463,2464],"Conduct Disorder","Attention Defict Hyperactivity Disorder",[2448],{"trials":2467,"activeCount":98},[],{"trials":2469,"activeCount":98},[],{"trials":2471,"activeCount":98},[],{"intervention":2473,"totalTrials":94,"cells":2474},"Dehydroepiandrosterone",{"EARLY_PHASE1":2475,"PHASE1":2477,"PHASE2":2479,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2476,"activeCount":98},[],{"trials":2478,"activeCount":98},[],{"trials":2480,"activeCount":98},[2481],{"nctId":2482,"briefTitle":2483,"status":140,"phases":2484,"completion":2485,"start":2486,"enrollment":226,"conditions":2487,"interventions":2489},"NCT00001487","Treatment of Mid-Life-Related Mood Disorders",[87],"2004-04","1995-06",[2488,29],"Depressive Disorder",[2473],{"trials":2491,"activeCount":98},[],{"trials":2493,"activeCount":98},[],{"trials":2495,"activeCount":98},[],{"intervention":2497,"totalTrials":94,"cells":2498},"buproprion",{"EARLY_PHASE1":2499,"PHASE1":2501,"PHASE2":2503,"PHASE3":2513,"PHASE4":2515,"NA":2517},{"trials":2500,"activeCount":98},[],{"trials":2502,"activeCount":98},[],{"trials":2504,"activeCount":98},[2505],{"nctId":2506,"briefTitle":2507,"status":140,"phases":2508,"completion":587,"start":2486,"enrollment":2509,"conditions":2510,"interventions":2511},"NCT00001483","Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression",[87],75,[21,2488],[2497,532,2512],"venlafaxine",{"trials":2514,"activeCount":98},[],{"trials":2516,"activeCount":98},[],{"trials":2518,"activeCount":98},[],{"intervention":2512,"totalTrials":94,"cells":2520},{"EARLY_PHASE1":2521,"PHASE1":2523,"PHASE2":2525,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2522,"activeCount":98},[],{"trials":2524,"activeCount":98},[],{"trials":2526,"activeCount":98},[2527],{"nctId":2506,"briefTitle":2507,"status":140,"phases":2528,"completion":587,"start":2486,"enrollment":2509,"conditions":2529,"interventions":2530},[87],[21,2488],[2497,532,2512],{"trials":2532,"activeCount":98},[],{"trials":2534,"activeCount":98},[],{"trials":2536,"activeCount":98},[],{"intervention":2538,"totalTrials":94,"cells":2539},"D-Cycloserine",{"EARLY_PHASE1":2540,"PHASE1":2542,"PHASE2":2544,"PHASE3":2556,"PHASE4":2558,"NA":2560},{"trials":2541,"activeCount":98},[],{"trials":2543,"activeCount":98},[],{"trials":2545,"activeCount":98},[2546],{"nctId":2547,"briefTitle":2548,"status":140,"phases":2549,"primaryCompletion":1425,"completion":2550,"start":1179,"enrollment":1377,"conditions":2551,"interventions":2555},"NCT00128401","Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia",[87],"2012-08",[2552,2553,2554],"Phobic Disorders","Anxiety","Social Phobia",[2538],{"trials":2557,"activeCount":98},[],{"trials":2559,"activeCount":98},[],{"trials":2561,"activeCount":98},[],{"intervention":2563,"totalTrials":94,"cells":2564},"Gabapentin",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2569,"PHASE3":2580,"PHASE4":2582,"NA":2584},{"trials":2566,"activeCount":98},[],{"trials":2568,"activeCount":98},[],{"trials":2570,"activeCount":98},[2571],{"nctId":2572,"briefTitle":2573,"status":140,"phases":2574,"completion":2575,"start":2576,"enrollment":226,"conditions":2577,"interventions":2578},"NCT00001482","New Drugs in the Treatment of Mood Disorders",[87],"2001-05","1995-05",[672,29,602],[2579,2563],"Lamotrigine",{"trials":2581,"activeCount":98},[],{"trials":2583,"activeCount":98},[],{"trials":2585,"activeCount":98},[],{"intervention":1546,"totalTrials":94,"cells":2587},{"EARLY_PHASE1":2588,"PHASE1":2590,"PHASE2":2592,"PHASE3":2598,"PHASE4":2600,"NA":2602},{"trials":2589,"activeCount":98},[],{"trials":2591,"activeCount":98},[],{"trials":2593,"activeCount":98},[2594],{"nctId":1538,"briefTitle":1539,"status":140,"phases":2595,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":1543,"conditions":2596,"interventions":2597},[86,87],[112],[1546,1535,1505],{"trials":2599,"activeCount":98},[],{"trials":2601,"activeCount":98},[],{"trials":2603,"activeCount":98},[],{"intervention":2605,"totalTrials":94,"cells":2606},"Tolcapone",{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2620,"PHASE4":2622,"NA":2624},{"trials":2608,"activeCount":98},[],{"trials":2610,"activeCount":98},[],{"trials":2612,"activeCount":98},[2613],{"nctId":2614,"briefTitle":2615,"status":150,"phases":2616,"primaryCompletion":1374,"completion":1374,"start":1834,"enrollment":2617,"conditions":2618,"interventions":2619},"NCT00044083","Clinical Trial of Tolcapone for Cognition in Schizophrenia",[87],210,[24],[2605],{"trials":2621,"activeCount":98},[],{"trials":2623,"activeCount":98},[],{"trials":2625,"activeCount":98},[],{"intervention":2627,"totalTrials":94,"cells":2628},"Ethinyl Estradiol\u002FDrospirenone",{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2646,"PHASE4":2648,"NA":2650},{"trials":2630,"activeCount":98},[],{"trials":2632,"activeCount":98},[],{"trials":2634,"activeCount":98},[2635],{"nctId":2636,"briefTitle":2637,"status":150,"phases":2638,"primaryCompletion":1152,"completion":1152,"start":2639,"enrollment":563,"conditions":2640,"interventions":2644},"NCT00089414","Treatment of Menstrually Related Disorders With Continuous v. Interrupted Oral Contraceptives",[87],"2004-07",[1518,2641,2642,2643,18],"PMS","Premenstrual Dysphoric Disorder","PMDD",[2627,2645],"CDB 2914",{"trials":2647,"activeCount":98},[],{"trials":2649,"activeCount":98},[],{"trials":2651,"activeCount":98},[],{"intervention":2645,"totalTrials":94,"cells":2653},{"EARLY_PHASE1":2654,"PHASE1":2656,"PHASE2":2658,"PHASE3":2664,"PHASE4":2666,"NA":2668},{"trials":2655,"activeCount":98},[],{"trials":2657,"activeCount":98},[],{"trials":2659,"activeCount":98},[2660],{"nctId":2636,"briefTitle":2637,"status":150,"phases":2661,"primaryCompletion":1152,"completion":1152,"start":2639,"enrollment":563,"conditions":2662,"interventions":2663},[87],[1518,2641,2642,2643,18],[2627,2645],{"trials":2665,"activeCount":98},[],{"trials":2667,"activeCount":98},[],{"trials":2669,"activeCount":98},[],{"intervention":2671,"totalTrials":94,"cells":2672},"Tamoxifen",{"EARLY_PHASE1":2673,"PHASE1":2675,"PHASE2":2677,"PHASE3":2687,"PHASE4":2689,"NA":2691},{"trials":2674,"activeCount":98},[],{"trials":2676,"activeCount":98},[],{"trials":2678,"activeCount":98},[2679],{"nctId":2680,"briefTitle":2681,"status":140,"phases":2682,"completion":2683,"start":2684,"enrollment":656,"conditions":2685,"interventions":2686},"NCT00026585","Examination of Tamoxifen in Acute Mania in Patients With Bipolar I Disorder",[87],"2007-11-02","2001-11-09",[21],[2671],{"trials":2688,"activeCount":98},[],{"trials":2690,"activeCount":98},[],{"trials":2692,"activeCount":98},[],{"intervention":2694,"totalTrials":94,"cells":2695},"MDL100.907",{"EARLY_PHASE1":2696,"PHASE1":2698,"PHASE2":2700,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2697,"activeCount":98},[],{"trials":2699,"activeCount":98},[],{"trials":2701,"activeCount":98},[2702],{"nctId":2703,"briefTitle":2704,"status":140,"phases":2705,"completion":654,"start":655,"enrollment":2706,"conditions":2707,"interventions":2708},"NCT00070694","An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression",[87],96,[2488],[2694],{"trials":2710,"activeCount":98},[],{"trials":2712,"activeCount":98},[],{"trials":2714,"activeCount":98},[],{"intervention":2716,"totalTrials":94,"cells":2717},"Novasoy",{"EARLY_PHASE1":2718,"PHASE1":2720,"PHASE2":2722,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2719,"activeCount":98},[],{"trials":2721,"activeCount":98},[],{"trials":2723,"activeCount":98},[2724],{"nctId":2725,"briefTitle":2726,"status":140,"phases":2727,"completion":2728,"start":2729,"enrollment":2730,"conditions":2731,"interventions":2732},"NCT00042380","Examination of a Soy-Based Supplement for Major Depression",[87],"2005-04","2002-07",120,[18],[2716],{"trials":2734,"activeCount":98},[],{"trials":2736,"activeCount":98},[],{"trials":2738,"activeCount":98},[],{"intervention":245,"totalTrials":94,"cells":2740},{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2742,"activeCount":98},[],{"trials":2744,"activeCount":98},[],{"trials":2746,"activeCount":98},[2747],{"nctId":235,"briefTitle":236,"status":150,"phases":2748,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":2749,"interventions":2750},[87],[243],[83,59,245,246],{"trials":2752,"activeCount":98},[],{"trials":2754,"activeCount":98},[],{"trials":2756,"activeCount":98},[],{"intervention":2758,"totalTrials":231,"cells":2759},"[C-11]PBR28",{"EARLY_PHASE1":2760,"PHASE1":2762,"PHASE2":2780,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2761,"activeCount":98},[],{"trials":2763,"activeCount":98},[2764,2773],{"nctId":2765,"briefTitle":2766,"status":140,"phases":2767,"completion":2768,"start":2769,"enrollment":27,"conditions":2770,"interventions":2772},"NCT00526916","PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28",[86],"2014-09-05","2007-09-04",[2771,15],"Neurocysticercosis",[2758],{"nctId":2774,"briefTitle":2775,"status":140,"phases":2776,"primaryCompletion":2290,"completion":2290,"start":1787,"enrollment":563,"conditions":2777,"interventions":2779},"NCT00547976","PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis",[86],[2778,15],"Atherosclerosis",[2758],{"trials":2781,"activeCount":98},[],{"trials":2783,"activeCount":98},[],{"trials":2785,"activeCount":98},[],{"trials":2787,"activeCount":98},[],{"intervention":2789,"totalTrials":94,"cells":2790},"[18F] SPA-RQ",{"EARLY_PHASE1":2791,"PHASE1":2793,"PHASE2":2804,"PHASE3":2806,"PHASE4":2808,"NA":2810},{"trials":2792,"activeCount":98},[],{"trials":2794,"activeCount":98},[2795],{"nctId":2796,"briefTitle":2797,"status":140,"phases":2798,"completion":2799,"start":2800,"enrollment":2801,"conditions":2802,"interventions":2803},"NCT00088738","Evaluation of Substance P Neurotransmission in Panic Disorder by PET Imaging of NK1 Receptors With [18F]SPA-RQ",[86],"2008-09-10","2004-07-27",84,[612,15],[2789],{"trials":2805,"activeCount":98},[],{"trials":2807,"activeCount":98},[],{"trials":2809,"activeCount":98},[],{"trials":2811,"activeCount":98},[],{"intervention":2813,"totalTrials":94,"cells":2814},"[11C]MePPEP",{"EARLY_PHASE1":2815,"PHASE1":2817,"PHASE2":2827,"PHASE3":2829,"PHASE4":2831,"NA":2833},{"trials":2816,"activeCount":98},[],{"trials":2818,"activeCount":98},[2819],{"nctId":2820,"briefTitle":2821,"status":140,"phases":2822,"primaryCompletion":2823,"completion":2823,"start":2824,"enrollment":1448,"conditions":2825,"interventions":2826},"NCT00598390","PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP",[86],"2013-01-22","2008-01-08",[15],[2813],{"trials":2828,"activeCount":98},[],{"trials":2830,"activeCount":98},[],{"trials":2832,"activeCount":98},[],{"trials":2834,"activeCount":98},[],{"intervention":2836,"totalTrials":94,"cells":2837},"18F-SF12051",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2850,"PHASE3":2852,"PHASE4":2854,"NA":2856},{"trials":2839,"activeCount":98},[],{"trials":2841,"activeCount":98},[2842],{"nctId":2843,"briefTitle":2844,"status":150,"phases":2845,"primaryCompletion":2846,"completion":239,"start":2847,"enrollment":9,"conditions":2848,"interventions":2849},"NCT05564429","[18F]SF12051 for Imaging the 18-kDa Translocator Protein (TSPO) in Brain and Whole Body of Healthy Subjects",[86],"2023-05-09","2023-02-02",[15],[2836],{"trials":2851,"activeCount":98},[],{"trials":2853,"activeCount":98},[],{"trials":2855,"activeCount":98},[],{"trials":2857,"activeCount":98},[],{"intervention":2859,"totalTrials":94,"cells":2860},"11C-ER176",{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2875,"PHASE3":2877,"PHASE4":2879,"NA":2881},{"trials":2862,"activeCount":98},[],{"trials":2864,"activeCount":98},[2865],{"nctId":2866,"briefTitle":2867,"status":150,"phases":2868,"primaryCompletion":2869,"completion":2870,"start":2871,"enrollment":35,"conditions":2872,"interventions":2873},"NCT03958630","PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand",[86],"2021-05-27","2023-12-04","2019-07-03",[217],[2859,2874],"11C-PIB",{"trials":2876,"activeCount":98},[],{"trials":2878,"activeCount":98},[],{"trials":2880,"activeCount":98},[],{"trials":2882,"activeCount":98},[],{"intervention":2874,"totalTrials":94,"cells":2884},{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2893,"PHASE3":2895,"PHASE4":2897,"NA":2899},{"trials":2886,"activeCount":98},[],{"trials":2888,"activeCount":98},[2889],{"nctId":2866,"briefTitle":2867,"status":150,"phases":2890,"primaryCompletion":2869,"completion":2870,"start":2871,"enrollment":35,"conditions":2891,"interventions":2892},[86],[217],[2859,2874],{"trials":2894,"activeCount":98},[],{"trials":2896,"activeCount":98},[],{"trials":2898,"activeCount":98},[],{"trials":2900,"activeCount":98},[],{"intervention":2902,"totalTrials":94,"cells":2903},"(2R,6R)-Hydroxynorketamine hydrochloride",{"EARLY_PHASE1":2904,"PHASE1":2906,"PHASE2":2917,"PHASE3":2919,"PHASE4":2921,"NA":2923},{"trials":2905,"activeCount":98},[],{"trials":2907,"activeCount":98},[2908],{"nctId":2909,"briefTitle":2910,"status":140,"phases":2911,"primaryCompletion":2912,"completion":2913,"start":2914,"enrollment":1531,"conditions":2915,"interventions":2916},"NCT04711005","Phase 1 Evaluation of (2R,6R)-Hydroxynorketamine",[86],"2023-04-30","2023-05-31","2021-01-11",[26],[2902],{"trials":2918,"activeCount":98},[],{"trials":2920,"activeCount":98},[],{"trials":2922,"activeCount":98},[],{"trials":2924,"activeCount":98},[],{"intervention":2926,"totalTrials":94,"cells":2927},"[11C] (-)-RWAY",{"EARLY_PHASE1":2928,"PHASE1":2930,"PHASE2":2940,"PHASE3":2942,"PHASE4":2944,"NA":2946},{"trials":2929,"activeCount":98},[],{"trials":2931,"activeCount":98},[2932],{"nctId":2933,"briefTitle":2934,"status":140,"phases":2935,"completion":2132,"start":2936,"enrollment":2937,"conditions":2938,"interventions":2939},"NCT00263523","PET Imaging of Brain 5-HT(1A) Receptors Using [(11)C](-)-RWAY",[86],"2005-12-05",15,[112],[2926],{"trials":2941,"activeCount":98},[],{"trials":2943,"activeCount":98},[],{"trials":2945,"activeCount":98},[],{"trials":2947,"activeCount":98},[],{"intervention":2949,"totalTrials":94,"cells":2950},"Modafinil",{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2964,"PHASE3":2966,"PHASE4":2968,"NA":2970},{"trials":2952,"activeCount":98},[],{"trials":2954,"activeCount":98},[2955],{"nctId":2956,"briefTitle":2957,"status":140,"phases":2958,"primaryCompletion":2959,"completion":2959,"start":2960,"enrollment":2961,"conditions":2962,"interventions":2963},"NCT00057707","Effects of Modafinil on Brain Function in Patients With Schizophrenia",[86],"2017-06-16","2003-03-26",176,[24,734],[2949],{"trials":2965,"activeCount":98},[],{"trials":2967,"activeCount":98},[],{"trials":2969,"activeCount":98},[],{"trials":2971,"activeCount":98},[],{"intervention":2973,"totalTrials":94,"cells":2974},"Dutasteride",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2987,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2976,"activeCount":98},[],{"trials":2978,"activeCount":98},[2979],{"nctId":2980,"briefTitle":2981,"status":140,"phases":2982,"primaryCompletion":2983,"completion":2983,"start":2984,"enrollment":22,"conditions":2985,"interventions":2986},"NCT00082043","Dutasteride to Treat Women With Menstrually Related Mood Disorders",[86],"2014-03-06","2004-03-31",[1518,2641,15,18],[2973],{"trials":2988,"activeCount":98},[],{"trials":2990,"activeCount":98},[],{"trials":2992,"activeCount":98},[],{"trials":2994,"activeCount":98},[],{"intervention":2996,"totalTrials":94,"cells":2997},"[C-11](R)-rolipram",{"EARLY_PHASE1":2998,"PHASE1":3000,"PHASE2":3012,"PHASE3":3014,"PHASE4":3016,"NA":3018},{"trials":2999,"activeCount":98},[],{"trials":3001,"activeCount":98},[3002],{"nctId":3003,"briefTitle":3004,"status":140,"phases":3005,"primaryCompletion":3006,"completion":3006,"start":3007,"enrollment":3008,"conditions":3009,"interventions":3011},"NCT00250172","PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram",[86],"2009-02-05","2005-10-31",26,[3010,15],"Dosimetry",[2996],{"trials":3013,"activeCount":98},[],{"trials":3015,"activeCount":98},[],{"trials":3017,"activeCount":98},[],{"trials":3019,"activeCount":98},[],{"intervention":298,"totalTrials":94,"cells":3021},{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3030,"PHASE3":3032,"PHASE4":3034,"NA":3036},{"trials":3023,"activeCount":98},[],{"trials":3025,"activeCount":98},[3026],{"nctId":287,"briefTitle":288,"status":150,"phases":3027,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":3028,"interventions":3029},[86],[294,295,296,112],[83,246,298],{"trials":3031,"activeCount":98},[],{"trials":3033,"activeCount":98},[],{"trials":3035,"activeCount":98},[],{"trials":3037,"activeCount":98},[],{"intervention":3039,"totalTrials":94,"cells":3040},"Emapunil",{"EARLY_PHASE1":3041,"PHASE1":3043,"PHASE2":3057,"PHASE3":3059,"PHASE4":3061,"NA":3063},{"trials":3042,"activeCount":98},[],{"trials":3044,"activeCount":98},[3045],{"nctId":3046,"briefTitle":3047,"status":140,"phases":3048,"primaryCompletion":3049,"completion":3050,"start":3051,"enrollment":3052,"conditions":3053,"interventions":3056},"NCT02181582","Specific PET Radioligand Binding to Translocator Protein",[86],"2016-06-16","2016-11-23","2014-06-24",32,[3054,3055],"Baseline","Blocking Receptor Binding",[3039],{"trials":3058,"activeCount":98},[],{"trials":3060,"activeCount":98},[],{"trials":3062,"activeCount":98},[],{"trials":3064,"activeCount":98},[],{"intervention":1521,"totalTrials":94,"cells":3066},{"EARLY_PHASE1":3067,"PHASE1":3069,"PHASE2":3075,"PHASE3":3077,"PHASE4":3079,"NA":3081},{"trials":3068,"activeCount":98},[],{"trials":3070,"activeCount":98},[3071],{"nctId":1512,"briefTitle":1513,"status":140,"phases":3072,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":226,"conditions":3073,"interventions":3074},[86],[1518,1519],[1521,1522,1505],{"trials":3076,"activeCount":98},[],{"trials":3078,"activeCount":98},[],{"trials":3080,"activeCount":98},[],{"trials":3082,"activeCount":98},[],{"intervention":1522,"totalTrials":94,"cells":3084},{"EARLY_PHASE1":3085,"PHASE1":3087,"PHASE2":3093,"PHASE3":3095,"PHASE4":3097,"NA":3099},{"trials":3086,"activeCount":98},[],{"trials":3088,"activeCount":98},[3089],{"nctId":1512,"briefTitle":1513,"status":140,"phases":3090,"primaryCompletion":1515,"completion":1515,"start":1516,"enrollment":226,"conditions":3091,"interventions":3092},[86],[1518,1519],[1521,1522,1505],{"trials":3094,"activeCount":98},[],{"trials":3096,"activeCount":98},[],{"trials":3098,"activeCount":98},[],{"trials":3100,"activeCount":98},[],{"intervention":3102,"totalTrials":94,"cells":3103},"Lysodase",{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3117,"PHASE3":3119,"PHASE4":3121,"NA":3123},{"trials":3105,"activeCount":98},[],{"trials":3107,"activeCount":98},[3108],{"nctId":3109,"briefTitle":3110,"status":140,"phases":3111,"completion":3112,"start":3113,"enrollment":27,"conditions":3114,"interventions":3116},"NCT00001410","PEG-Glucocerebrosidase for the Treatment of Gaucher Disease",[86],"2001-12","1993-10",[3115],"Gaucher's Disease",[3102],{"trials":3118,"activeCount":98},[],{"trials":3120,"activeCount":98},[],{"trials":3122,"activeCount":98},[],{"trials":3124,"activeCount":98},[],{"intervention":3126,"totalTrials":94,"cells":3127},"Oxytocin",{"EARLY_PHASE1":3128,"PHASE1":3130,"PHASE2":3142,"PHASE3":3144,"PHASE4":3146,"NA":3148},{"trials":3129,"activeCount":98},[],{"trials":3131,"activeCount":98},[3132],{"nctId":3133,"briefTitle":3134,"status":140,"phases":3135,"primaryCompletion":3136,"completion":3136,"start":3137,"enrollment":3138,"conditions":3139,"interventions":3140},"NCT01093768","Brain Imaging Study of Adults With Autism Spectrum Disorders",[86],"2013-04-11","2010-02-19",38,[1670],[3126,3141],"Vasopressin",{"trials":3143,"activeCount":98},[],{"trials":3145,"activeCount":98},[],{"trials":3147,"activeCount":98},[],{"trials":3149,"activeCount":98},[],{"intervention":3141,"totalTrials":94,"cells":3151},{"EARLY_PHASE1":3152,"PHASE1":3154,"PHASE2":3160,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3153,"activeCount":98},[],{"trials":3155,"activeCount":98},[3156],{"nctId":3133,"briefTitle":3134,"status":140,"phases":3157,"primaryCompletion":3136,"completion":3136,"start":3137,"enrollment":3138,"conditions":3158,"interventions":3159},[86],[1670],[3126,3141],{"trials":3161,"activeCount":98},[],{"trials":3163,"activeCount":98},[],{"trials":3165,"activeCount":98},[],{"trials":3167,"activeCount":98},[],{"intervention":3169,"totalTrials":94,"cells":3170},"[(11)C] PBR28",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3183,"PHASE3":3185,"PHASE4":3187,"NA":3189},{"trials":3172,"activeCount":98},[],{"trials":3174,"activeCount":98},[3175],{"nctId":3176,"briefTitle":3177,"status":140,"phases":3178,"completion":3179,"start":3180,"enrollment":599,"conditions":3181,"interventions":3182},"NCT00283920","PET Imaging of Brain Peripheral Benzodiazepine Receptors",[86],"2007-10-02","2006-01-26",[327],[3169],{"trials":3184,"activeCount":98},[],{"trials":3186,"activeCount":98},[],{"trials":3188,"activeCount":98},[],{"trials":3190,"activeCount":98},[],{"intervention":3192,"totalTrials":94,"cells":3193},"[11C]NNC-112",{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3204,"PHASE3":3206,"PHASE4":3208,"NA":3210},{"trials":3195,"activeCount":98},[],{"trials":3197,"activeCount":98},[3198],{"nctId":3199,"briefTitle":3200,"status":140,"phases":3201,"completion":1762,"start":2639,"enrollment":9,"conditions":3202,"interventions":3203},"NCT00088517","Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112",[86],[15],[3192],{"trials":3205,"activeCount":98},[],{"trials":3207,"activeCount":98},[],{"trials":3209,"activeCount":98},[],{"trials":3211,"activeCount":98},[],{"intervention":3213,"totalTrials":94,"cells":3214},"[18F]SP203",{"EARLY_PHASE1":3215,"PHASE1":3217,"PHASE2":3232,"PHASE3":3234,"PHASE4":3236,"NA":3238},{"trials":3216,"activeCount":98},[],{"trials":3218,"activeCount":98},[3219],{"nctId":3220,"briefTitle":3221,"status":140,"phases":3222,"completion":3223,"start":3224,"enrollment":656,"conditions":3225,"interventions":3231},"NCT00538798","PET Imaging of Brain mGluR5 Receptors Using [18F]SP203",[86],"2015-03-17","2007-09-28",[15,3226,3227,3228,3229,3230],"Glutamate Receptor","mGlur5 Protein","Excitatory Amino Acid Receptors","Drug Kinetics","PET Scan",[3213],{"trials":3233,"activeCount":98},[],{"trials":3235,"activeCount":98},[],{"trials":3237,"activeCount":98},[],{"trials":3239,"activeCount":98},[],{"intervention":3241,"totalTrials":94,"cells":3242},"11(R)-rolipram",{"EARLY_PHASE1":3243,"PHASE1":3245,"PHASE2":3254,"PHASE3":3256,"PHASE4":3258,"NA":3260},{"trials":3244,"activeCount":98},[],{"trials":3246,"activeCount":98},[3247],{"nctId":3248,"briefTitle":3249,"status":150,"phases":3250,"primaryCompletion":3251,"completion":239,"start":3251,"enrollment":94,"conditions":3252,"interventions":3253},"NCT05522673","[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine",[86],"2023-02-08",[18],[3241],{"trials":3255,"activeCount":98},[],{"trials":3257,"activeCount":98},[],{"trials":3259,"activeCount":98},[],{"trials":3261,"activeCount":98},[],{"intervention":3263,"totalTrials":94,"cells":3264},"MK-0657",{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3276,"PHASE3":3278,"PHASE4":3280,"NA":3282},{"trials":3266,"activeCount":98},[],{"trials":3268,"activeCount":98},[3269],{"nctId":3270,"briefTitle":3271,"status":140,"phases":3272,"primaryCompletion":2290,"completion":2290,"start":3273,"enrollment":563,"conditions":3274,"interventions":3275},"NCT00472576","Antidepressant Effects of NR2B in Major Depression",[86],"2007-05",[397],[3263],{"trials":3277,"activeCount":98},[],{"trials":3279,"activeCount":98},[],{"trials":3281,"activeCount":98},[],{"trials":3283,"activeCount":98},[],{"intervention":3285,"totalTrials":94,"cells":3286},"[11C]LY2428703",{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3300,"PHASE3":3302,"PHASE4":3304,"NA":3306},{"trials":3288,"activeCount":98},[],{"trials":3290,"activeCount":98},[3291],{"nctId":3292,"briefTitle":3293,"status":150,"phases":3294,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":170,"conditions":3297,"interventions":3299},"NCT01420952","Imaging of Brain Receptors Using (11C)mGlu1",[86],"2012-11-27","2011-07-29",[3010,3298],"Pharmacokinetics",[3285],{"trials":3301,"activeCount":98},[],{"trials":3303,"activeCount":98},[],{"trials":3305,"activeCount":98},[],{"trials":3307,"activeCount":98},[],{"intervention":3309,"totalTrials":94,"cells":3310},"STX107",{"EARLY_PHASE1":3311,"PHASE1":3313,"PHASE2":3323,"PHASE3":3325,"PHASE4":3327,"NA":3329},{"trials":3312,"activeCount":98},[],{"trials":3314,"activeCount":98},[3315],{"nctId":3316,"briefTitle":3317,"status":140,"phases":3318,"primaryCompletion":3049,"completion":3049,"start":3319,"enrollment":1448,"conditions":3320,"interventions":3322},"NCT01896843","Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain",[86],"2013-06-27",[3321],"mGluR5 Receptors",[3309],{"trials":3324,"activeCount":98},[],{"trials":3326,"activeCount":98},[],{"trials":3328,"activeCount":98},[],{"trials":3330,"activeCount":98},[],{"intervention":3332,"totalTrials":94,"cells":3333},"[F-18]FBR",{"EARLY_PHASE1":3334,"PHASE1":3336,"PHASE2":3346,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3335,"activeCount":98},[],{"trials":3337,"activeCount":98},[3338],{"nctId":3339,"briefTitle":3340,"status":140,"phases":3341,"primaryCompletion":3342,"completion":3342,"start":2769,"enrollment":3343,"conditions":3344,"interventions":3345},"NCT00527579","PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB",[86],"2013-11-26",24,[2771,15],[3332],{"trials":3347,"activeCount":98},[],{"trials":3349,"activeCount":98},[],{"trials":3351,"activeCount":98},[],{"trials":3353,"activeCount":98},[],{"intervention":3355,"totalTrials":94,"cells":3356},"[(11)C] MePPEP",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3369,"PHASE3":3371,"PHASE4":3373,"NA":3375},{"trials":3358,"activeCount":98},[],{"trials":3360,"activeCount":98},[3361],{"nctId":3362,"briefTitle":3363,"status":140,"phases":3364,"primaryCompletion":3365,"start":3366,"enrollment":599,"conditions":3367,"interventions":3368},"NCT00450021","Imaging of Cannabinoid Receptors Using New Radioactive Tracer",[86],"2008-02-06","2007-03-19",[15],[3355],{"trials":3370,"activeCount":98},[],{"trials":3372,"activeCount":98},[],{"trials":3374,"activeCount":98},[],{"trials":3376,"activeCount":98},[],{"intervention":3378,"totalTrials":94,"cells":3379},"Rolipram",{"EARLY_PHASE1":3380,"PHASE1":3382,"PHASE2":3392,"PHASE3":3394,"PHASE4":3396,"NA":3398},{"trials":3381,"activeCount":98},[],{"trials":3383,"activeCount":98},[3384],{"nctId":3385,"briefTitle":3386,"status":140,"phases":3387,"primaryCompletion":3049,"completion":3388,"start":3389,"enrollment":1543,"conditions":3390,"interventions":3391},"NCT00369798","Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients",[86],"2016-10-12","2006-08-02",[26,15],[3378],{"trials":3393,"activeCount":98},[],{"trials":3395,"activeCount":98},[],{"trials":3397,"activeCount":98},[],{"trials":3399,"activeCount":98},[],{"intervention":3401,"totalTrials":94,"cells":3402},"[18F]FMPEP-d2",{"EARLY_PHASE1":3403,"PHASE1":3405,"PHASE2":3418,"PHASE3":3420,"PHASE4":3422,"NA":3424},{"trials":3404,"activeCount":98},[],{"trials":3406,"activeCount":98},[3407],{"nctId":3408,"briefTitle":3409,"status":140,"phases":3410,"primaryCompletion":730,"completion":730,"start":3411,"enrollment":27,"conditions":3412,"interventions":3417},"NCT00598286","PET Imaging of Cannabinoid CB1 Receptors Using [18F]FMPEP-d2",[86],"2008-01",[3413,3414,3415,3416],"CB1","Cannabinoid","PET","Brain Imaging",[3401],{"trials":3419,"activeCount":98},[],{"trials":3421,"activeCount":98},[],{"trials":3423,"activeCount":98},[],{"trials":3425,"activeCount":98},[],{"intervention":3427,"totalTrials":94,"cells":3428},"Cyclophosphamate",{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3441,"PHASE3":3443,"PHASE4":3445,"NA":3447},{"trials":3430,"activeCount":98},[],{"trials":3432,"activeCount":98},[3433],{"nctId":3434,"briefTitle":3435,"status":140,"phases":3436,"completion":3437,"start":3438,"enrollment":226,"conditions":3439,"interventions":3440},"NCT00013650","Effects of an Anti-Inflammatory Drug in Alzheimer's Disease",[86],"2008-04-21","2001-03-22",[218],[3427],{"trials":3442,"activeCount":98},[],{"trials":3444,"activeCount":98},[],{"trials":3446,"activeCount":98},[],{"trials":3448,"activeCount":98},[],{"intervention":3450,"totalTrials":94,"cells":3451},"[C-11]PRB28",{"EARLY_PHASE1":3452,"PHASE1":3454,"PHASE2":3464,"PHASE3":3466,"PHASE4":3468,"NA":3470},{"trials":3453,"activeCount":98},[],{"trials":3455,"activeCount":98},[3456],{"nctId":3457,"briefTitle":3458,"status":140,"phases":3459,"completion":2313,"start":3460,"enrollment":3461,"conditions":3462,"interventions":3463},"NCT00407693","PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28",[86],"2006-11-28",51,[15],[3450],{"trials":3465,"activeCount":98},[],{"trials":3467,"activeCount":98},[],{"trials":3469,"activeCount":98},[],{"trials":3471,"activeCount":98},[],{"intervention":3473,"totalTrials":94,"cells":3474},"[11C]MeS-IMPY",{"EARLY_PHASE1":3475,"PHASE1":3477,"PHASE2":3487,"PHASE3":3489,"PHASE4":3491,"NA":3493},{"trials":3476,"activeCount":98},[],{"trials":3478,"activeCount":98},[3479],{"nctId":3480,"briefTitle":3481,"status":140,"phases":3482,"primaryCompletion":3483,"start":3484,"enrollment":180,"conditions":3485,"interventions":3486},"NCT00407576","PET Imaging of Brain Amyloid Using [11C]MeS-IMPY",[86],"2008-11-07","2006-12-01",[218,15],[3473],{"trials":3488,"activeCount":98},[],{"trials":3490,"activeCount":98},[],{"trials":3492,"activeCount":98},[],{"trials":3494,"activeCount":98},[],{"intervention":3496,"totalTrials":94,"cells":3497},"[11C]ER-176",{"EARLY_PHASE1":3498,"PHASE1":3508,"PHASE2":3510,"PHASE3":3512,"PHASE4":3514,"NA":3516},{"trials":3499,"activeCount":98},[3500],{"nctId":3501,"briefTitle":3502,"status":140,"phases":3503,"primaryCompletion":3049,"completion":3049,"start":3504,"enrollment":11,"conditions":3505,"interventions":3507},"NCT02147392","Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People",[85],"2014-05-14",[3298,3506],"Adult",[3496],{"trials":3509,"activeCount":98},[],{"trials":3511,"activeCount":98},[],{"trials":3513,"activeCount":98},[],{"trials":3515,"activeCount":98},[],{"trials":3517,"activeCount":98},[],{"intervention":3519,"totalTrials":94,"cells":3520},"NOP-1A",{"EARLY_PHASE1":3521,"PHASE1":3533,"PHASE2":3535,"PHASE3":3537,"PHASE4":3539,"NA":3541},{"trials":3522,"activeCount":98},[3523],{"nctId":3524,"briefTitle":3525,"status":140,"phases":3526,"completion":3527,"start":3528,"enrollment":3529,"conditions":3530,"interventions":3532},"NCT01198197","PET Brain and Whole Body Distribution Studies for Nociceptin\u002FOrphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A",[85],"2014-02-28","2010-09-03",41,[3531,2553,18],"Pain",[3519],{"trials":3534,"activeCount":98},[],{"trials":3536,"activeCount":98},[],{"trials":3538,"activeCount":98},[],{"trials":3540,"activeCount":98},[],{"trials":3542,"activeCount":98},[],{"intervention":604,"totalTrials":563,"cells":3544},{"EARLY_PHASE1":3545,"PHASE1":3547,"PHASE2":3549,"PHASE3":3551,"PHASE4":3553,"NA":3571},{"trials":3546,"activeCount":98},[],{"trials":3548,"activeCount":98},[],{"trials":3550,"activeCount":98},[],{"trials":3552,"activeCount":98},[],{"trials":3554,"activeCount":98},[3555,3559,3563,3567],{"nctId":594,"briefTitle":595,"status":140,"phases":3556,"primaryCompletion":597,"completion":597,"start":598,"enrollment":599,"conditions":3557,"interventions":3558},[89],[601,602,24],[604,562],{"nctId":727,"briefTitle":728,"status":140,"phases":3560,"primaryCompletion":730,"completion":690,"start":731,"enrollment":732,"conditions":3561,"interventions":3562},[89],[24,734],[736,604,737,714],{"nctId":616,"briefTitle":617,"status":140,"phases":3564,"completion":619,"start":620,"enrollment":621,"conditions":3565,"interventions":3566},[89],[24],[624,625,626,551,627,628,629],{"nctId":739,"briefTitle":740,"status":140,"phases":3568,"primaryCompletion":742,"completion":730,"start":743,"enrollment":744,"conditions":3569,"interventions":3570},[89],[24],[604,747,714,748,749,750],{"trials":3572,"activeCount":98},[3573],{"nctId":3574,"briefTitle":3575,"status":140,"phases":3576,"completion":654,"start":3577,"enrollment":3578,"conditions":3579,"interventions":3580},"NCT00015548","CATIE-Alzheimer's Disease Trial",[90],"2001-03",450,[218],[604,737,736,3581],"Citalopram",{"intervention":532,"totalTrials":563,"cells":3583},{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3594,"PHASE4":3596,"NA":3615},{"trials":3585,"activeCount":98},[],{"trials":3587,"activeCount":98},[],{"trials":3589,"activeCount":98},[3590],{"nctId":2506,"briefTitle":2507,"status":140,"phases":3591,"completion":587,"start":2486,"enrollment":2509,"conditions":3592,"interventions":3593},[87],[21,2488],[2497,532,2512],{"trials":3595,"activeCount":98},[],{"trials":3597,"activeCount":98},[3598,3602,3611],{"nctId":519,"briefTitle":520,"status":140,"phases":3599,"completion":522,"start":523,"enrollment":524,"conditions":3600,"interventions":3601},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"nctId":3603,"briefTitle":3604,"status":140,"phases":3605,"completion":586,"start":3606,"enrollment":164,"conditions":3607,"interventions":3610},"NCT00050804","Evaluation of Stress Disorders",[89],"2002-12",[3608,3609],"Acute Traumatic Stress Disorders","Post-Traumatic Stress Disorders",[532],{"nctId":701,"briefTitle":702,"status":140,"phases":3612,"primaryCompletion":704,"completion":705,"start":706,"enrollment":707,"conditions":3613,"interventions":3614},[89],[18],[678,710],{"trials":3616,"activeCount":98},[3617],{"nctId":3618,"briefTitle":3619,"status":140,"phases":3620,"completion":523,"start":3621,"conditions":3622,"interventions":3623},"NCT00005013","Treatment of Major Depression With St. John's Wort (Hypericum)",[90],"1998-12",[397],[710,3624],"Hypericum perforatum",{"intervention":736,"totalTrials":563,"cells":3626},{"EARLY_PHASE1":3627,"PHASE1":3629,"PHASE2":3631,"PHASE3":3633,"PHASE4":3644,"NA":3654},{"trials":3628,"activeCount":98},[],{"trials":3630,"activeCount":98},[],{"trials":3632,"activeCount":98},[],{"trials":3634,"activeCount":98},[3635],{"nctId":3636,"briefTitle":3637,"status":140,"phases":3638,"completion":3639,"start":1403,"enrollment":3640,"conditions":3641,"interventions":3643},"NCT00005014","Treatment of Autism in Children and Adolescents",[88],"2001-02",101,[3642],"Autistic Disorder",[736],{"trials":3645,"activeCount":98},[3646,3650],{"nctId":727,"briefTitle":728,"status":140,"phases":3647,"primaryCompletion":730,"completion":690,"start":731,"enrollment":732,"conditions":3648,"interventions":3649},[89],[24,734],[736,604,737,714],{"nctId":616,"briefTitle":617,"status":140,"phases":3651,"completion":619,"start":620,"enrollment":621,"conditions":3652,"interventions":3653},[89],[24],[624,625,626,551,627,628,629],{"trials":3655,"activeCount":98},[3656,3660],{"nctId":3574,"briefTitle":3575,"status":140,"phases":3657,"completion":654,"start":3577,"enrollment":3578,"conditions":3658,"interventions":3659},[90],[218],[604,737,736,3581],{"nctId":539,"briefTitle":540,"status":140,"phases":3661,"completion":542,"start":143,"enrollment":543,"conditions":3662,"interventions":3663},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":3581,"totalTrials":170,"cells":3665},{"EARLY_PHASE1":3666,"PHASE1":3668,"PHASE2":3670,"PHASE3":3672,"PHASE4":3674,"NA":3687},{"trials":3667,"activeCount":98},[],{"trials":3669,"activeCount":98},[],{"trials":3671,"activeCount":98},[],{"trials":3673,"activeCount":98},[],{"trials":3675,"activeCount":98},[3676,3680],{"nctId":519,"briefTitle":520,"status":140,"phases":3677,"completion":522,"start":523,"enrollment":524,"conditions":3678,"interventions":3679},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"nctId":3681,"briefTitle":3682,"status":140,"phases":3683,"primaryCompletion":1154,"completion":1154,"start":1351,"enrollment":3684,"conditions":3685,"interventions":3686},"NCT00047671","Ethnic Variations in Antidepressant Response",[89],400,[18],[3581],{"trials":3688,"activeCount":98},[3689],{"nctId":3574,"briefTitle":3575,"status":140,"phases":3690,"completion":654,"start":3577,"enrollment":3578,"conditions":3691,"interventions":3692},[90],[218],[604,737,736,3581],{"intervention":3694,"totalTrials":170,"cells":3695},"methylphenidate",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3702,"PHASE4":3704,"NA":3710},{"trials":3697,"activeCount":98},[],{"trials":3699,"activeCount":98},[],{"trials":3701,"activeCount":98},[],{"trials":3703,"activeCount":98},[],{"trials":3705,"activeCount":98},[3706],{"nctId":665,"briefTitle":666,"status":140,"phases":3707,"primaryCompletion":668,"completion":668,"start":669,"enrollment":670,"conditions":3708,"interventions":3709},[89],[672],[633,674],{"trials":3711,"activeCount":98},[3712,3722],{"nctId":3713,"briefTitle":3714,"status":140,"phases":3715,"primaryCompletion":587,"completion":587,"start":3716,"enrollment":2730,"conditions":3717,"interventions":3720},"NCT00012584","Treatment of Youth With ADHD and Anxiety",[90],"2000-11",[1884,3718,2554,3719],"Anxiety, Separation","Generalized Anxiety Disorder",[3694,3721],"fluvoxamine",{"nctId":3723,"briefTitle":3724,"status":140,"phases":3725,"primaryCompletion":3726,"start":845,"enrollment":226,"conditions":3727,"interventions":3730},"NCT00025779","Methylphenidate in Children and Adolescents With Pervasive Developmental Disorders",[90],"2003-11",[3728,3642,3729],"Attention Deficit Disorder With Hyperactivity","Pervasive Development Disorders",[3694,3731],"guanfacine",{"intervention":737,"totalTrials":170,"cells":3733},{"EARLY_PHASE1":3734,"PHASE1":3736,"PHASE2":3738,"PHASE3":3740,"PHASE4":3742,"NA":3752},{"trials":3735,"activeCount":98},[],{"trials":3737,"activeCount":98},[],{"trials":3739,"activeCount":98},[],{"trials":3741,"activeCount":98},[],{"trials":3743,"activeCount":98},[3744,3748],{"nctId":727,"briefTitle":728,"status":140,"phases":3745,"primaryCompletion":730,"completion":690,"start":731,"enrollment":732,"conditions":3746,"interventions":3747},[89],[24,734],[736,604,737,714],{"nctId":616,"briefTitle":617,"status":140,"phases":3749,"completion":619,"start":620,"enrollment":621,"conditions":3750,"interventions":3751},[89],[24],[624,625,626,551,627,628,629],{"trials":3753,"activeCount":98},[3754],{"nctId":3574,"briefTitle":3575,"status":140,"phases":3755,"completion":654,"start":3577,"enrollment":3578,"conditions":3756,"interventions":3757},[90],[218],[604,737,736,3581],{"intervention":533,"totalTrials":231,"cells":3759},{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3764,"PHASE3":3766,"PHASE4":3768,"NA":3774},{"trials":3761,"activeCount":98},[],{"trials":3763,"activeCount":98},[],{"trials":3765,"activeCount":98},[],{"trials":3767,"activeCount":98},[],{"trials":3769,"activeCount":98},[3770],{"nctId":519,"briefTitle":520,"status":140,"phases":3771,"completion":522,"start":523,"enrollment":524,"conditions":3772,"interventions":3773},[89],[18],[527,528,529,506,530,531,532,533,534,535],{"trials":3775,"activeCount":98},[3776],{"nctId":539,"briefTitle":540,"status":140,"phases":3777,"completion":542,"start":143,"enrollment":543,"conditions":3778,"interventions":3779},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":614,"totalTrials":231,"cells":3781},{"EARLY_PHASE1":3782,"PHASE1":3784,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3796},{"trials":3783,"activeCount":98},[],{"trials":3785,"activeCount":98},[],{"trials":3787,"activeCount":98},[],{"trials":3789,"activeCount":98},[],{"trials":3791,"activeCount":98},[3792],{"nctId":606,"briefTitle":607,"status":140,"phases":3793,"completion":609,"start":610,"enrollment":226,"conditions":3794,"interventions":3795},[89],[612],[614,562],{"trials":3797,"activeCount":98},[3798],{"nctId":539,"briefTitle":540,"status":140,"phases":3799,"completion":542,"start":143,"enrollment":543,"conditions":3800,"interventions":3801},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":3721,"totalTrials":231,"cells":3803},{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3808,"PHASE3":3810,"PHASE4":3822,"NA":3824},{"trials":3805,"activeCount":98},[],{"trials":3807,"activeCount":98},[],{"trials":3809,"activeCount":98},[],{"trials":3811,"activeCount":98},[3812],{"nctId":3813,"briefTitle":3814,"status":140,"phases":3815,"completion":3816,"start":3817,"conditions":3818,"interventions":3820},"NCT00000389","Treatment for Anxiety in Children",[88],"1999-11","1996-10",[1379,31,3719,2554,3819],"Separation Anxiety",[3821],"Fluvoxamine",{"trials":3823,"activeCount":98},[],{"trials":3825,"activeCount":98},[3826],{"nctId":3713,"briefTitle":3714,"status":140,"phases":3827,"primaryCompletion":587,"completion":587,"start":3716,"enrollment":2730,"conditions":3828,"interventions":3829},[90],[1884,3718,2554,3719],[3694,3721],{"intervention":3831,"totalTrials":231,"cells":3832},"Yohimbine",{"EARLY_PHASE1":3833,"PHASE1":3835,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3834,"activeCount":98},[],{"trials":3836,"activeCount":98},[],{"trials":3838,"activeCount":98},[],{"trials":3840,"activeCount":98},[],{"trials":3842,"activeCount":98},[],{"trials":3844,"activeCount":98},[3845,3851],{"nctId":3846,"briefTitle":3847,"status":140,"phases":3848,"completion":619,"start":576,"enrollment":1603,"conditions":3849,"interventions":3850},"NCT00029627","Brain Receptors in Sympathetic Nervous System Regulation",[],[15],[3831],{"nctId":3852,"briefTitle":3853,"status":140,"phases":3854,"completion":2085,"start":3855,"enrollment":3856,"conditions":3857,"interventions":3858},"NCT00032838","Effects of Stress Hormones on Emotion and Cognition",[],"2002-03",170,[15],[3831],{"intervention":2579,"totalTrials":231,"cells":3860},{"EARLY_PHASE1":3861,"PHASE1":3863,"PHASE2":3865,"PHASE3":3871,"PHASE4":3873,"NA":3875},{"trials":3862,"activeCount":98},[],{"trials":3864,"activeCount":98},[],{"trials":3866,"activeCount":98},[3867],{"nctId":2572,"briefTitle":2573,"status":140,"phases":3868,"completion":2575,"start":2576,"enrollment":226,"conditions":3869,"interventions":3870},[87],[672,29,602],[2579,2563],{"trials":3872,"activeCount":98},[],{"trials":3874,"activeCount":98},[],{"trials":3876,"activeCount":98},[3877],{"nctId":539,"briefTitle":540,"status":140,"phases":3878,"completion":542,"start":143,"enrollment":543,"conditions":3879,"interventions":3880},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":3882,"totalTrials":94,"cells":3883},"RU-486",{"EARLY_PHASE1":3884,"PHASE1":3886,"PHASE2":3888,"PHASE3":3890,"PHASE4":3892,"NA":3894},{"trials":3885,"activeCount":98},[],{"trials":3887,"activeCount":98},[],{"trials":3889,"activeCount":98},[],{"trials":3891,"activeCount":98},[],{"trials":3893,"activeCount":98},[],{"trials":3895,"activeCount":98},[3896],{"nctId":3897,"briefTitle":3898,"status":140,"phases":3899,"completion":654,"start":1180,"enrollment":3900,"conditions":3901,"interventions":3903},"NCT00046553","Brain Receptor Function in Post-Traumatic Stress Disorder",[],97,[3902],"Post-Traumatic Stress Disorder",[3882],{"intervention":3905,"totalTrials":94,"cells":3906},"Hypericum",{"EARLY_PHASE1":3907,"PHASE1":3909,"PHASE2":3911,"PHASE3":3913,"PHASE4":3915,"NA":3917},{"trials":3908,"activeCount":98},[],{"trials":3910,"activeCount":98},[],{"trials":3912,"activeCount":98},[],{"trials":3914,"activeCount":98},[],{"trials":3916,"activeCount":98},[],{"trials":3918,"activeCount":98},[3919],{"nctId":3920,"briefTitle":3921,"status":140,"phases":3922,"completion":1351,"start":3923,"enrollment":35,"conditions":3924,"interventions":3925},"NCT00001919","Neuroimaging of St. John's Wort-Induced Changes of Serotonin Metabolism in Normal Subjects",[],"1999-09",[15,29],[3905],{"intervention":3927,"totalTrials":94,"cells":3928},"[123] 5-I-A-85380",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3935,"PHASE4":3937,"NA":3939},{"trials":3930,"activeCount":98},[],{"trials":3932,"activeCount":98},[],{"trials":3934,"activeCount":98},[],{"trials":3936,"activeCount":98},[],{"trials":3938,"activeCount":98},[],{"trials":3940,"activeCount":98},[3941],{"nctId":3942,"briefTitle":3943,"status":140,"phases":3944,"completion":3945,"start":1351,"enrollment":357,"conditions":3946,"interventions":3947},"NCT00039702","Brain Imaging in Alzheimer's Disease",[],"2004-09",[1182],[3927],{"intervention":3949,"totalTrials":94,"cells":3950},"[11C]PBR28",{"EARLY_PHASE1":3951,"PHASE1":3953,"PHASE2":3955,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3952,"activeCount":98},[],{"trials":3954,"activeCount":98},[],{"trials":3956,"activeCount":98},[],{"trials":3958,"activeCount":98},[],{"trials":3960,"activeCount":98},[],{"trials":3962,"activeCount":98},[3963],{"nctId":3964,"briefTitle":3965,"status":150,"phases":3966,"primaryCompletion":3967,"completion":3967,"start":3968,"enrollment":357,"conditions":3969,"interventions":3975},"NCT00459693","PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)",[90],"2014-04-06","2007-04-09",[3970,3971,3972,3973,3974,1480,15],"HIV-Dementia","HIV-Associated Cognitive Motor Complex","AIDS Encephalopathy","AIDS Dementia Complex","AIDS-Related Dementia Complex",[3949],{"intervention":3977,"totalTrials":94,"cells":3978},"[11C]PS13",{"EARLY_PHASE1":3979,"PHASE1":3981,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3989},{"trials":3980,"activeCount":98},[],{"trials":3982,"activeCount":98},[],{"trials":3984,"activeCount":98},[],{"trials":3986,"activeCount":98},[],{"trials":3988,"activeCount":98},[],{"trials":3990,"activeCount":98},[3991],{"nctId":3992,"briefTitle":3993,"status":140,"phases":3994,"primaryCompletion":3995,"completion":239,"start":3996,"enrollment":1764,"conditions":3997,"interventions":3999},"NCT03324646","Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)",[],"2020-09-11","2017-10-03",[3998],"Normal Physiology",[3977],{"intervention":4001,"totalTrials":94,"cells":4002},"18F-OGA-1",{"EARLY_PHASE1":4003,"PHASE1":4005,"PHASE2":4007,"PHASE3":4009,"PHASE4":4011,"NA":4013},{"trials":4004,"activeCount":98},[],{"trials":4006,"activeCount":98},[],{"trials":4008,"activeCount":98},[],{"trials":4010,"activeCount":98},[],{"trials":4012,"activeCount":98},[],{"trials":4014,"activeCount":98},[4015],{"nctId":4016,"briefTitle":4017,"status":140,"phases":4018,"primaryCompletion":4019,"completion":4019,"start":4020,"enrollment":4021,"conditions":4022,"interventions":4023},"NCT03632226","Evaluation of a Novel PET Radioligand to Image OGA",[],"2019-06-25","2016-05-02",28,[3298,3506],[4001],{"intervention":3624,"totalTrials":94,"cells":4025},{"EARLY_PHASE1":4026,"PHASE1":4028,"PHASE2":4030,"PHASE3":4032,"PHASE4":4034,"NA":4036},{"trials":4027,"activeCount":98},[],{"trials":4029,"activeCount":98},[],{"trials":4031,"activeCount":98},[],{"trials":4033,"activeCount":98},[],{"trials":4035,"activeCount":98},[],{"trials":4037,"activeCount":98},[4038],{"nctId":3618,"briefTitle":3619,"status":140,"phases":4039,"completion":523,"start":3621,"conditions":4040,"interventions":4041},[90],[397],[710,3624],{"intervention":3731,"totalTrials":94,"cells":4043},{"EARLY_PHASE1":4044,"PHASE1":4046,"PHASE2":4048,"PHASE3":4050,"PHASE4":4052,"NA":4054},{"trials":4045,"activeCount":98},[],{"trials":4047,"activeCount":98},[],{"trials":4049,"activeCount":98},[],{"trials":4051,"activeCount":98},[],{"trials":4053,"activeCount":98},[],{"trials":4055,"activeCount":98},[4056],{"nctId":3723,"briefTitle":3724,"status":140,"phases":4057,"primaryCompletion":3726,"start":845,"enrollment":226,"conditions":4058,"interventions":4059},[90],[3728,3642,3729],[3694,3731],{"intervention":4061,"totalTrials":94,"cells":4062},"18F-Fluoro-L-dopa",{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4067,"PHASE3":4069,"PHASE4":4071,"NA":4073},{"trials":4064,"activeCount":98},[],{"trials":4066,"activeCount":98},[],{"trials":4068,"activeCount":98},[],{"trials":4070,"activeCount":98},[],{"trials":4072,"activeCount":98},[],{"trials":4074,"activeCount":98},[4075],{"nctId":4076,"briefTitle":4077,"status":140,"phases":4078,"start":4079,"enrollment":4080,"conditions":4081,"interventions":4082},"NCT00024622","PET Scanning in Parkinson s Disease",[],"2002-03-15",502,[24,216],[4061,4083],"O-15 Water",{"intervention":4083,"totalTrials":94,"cells":4085},{"EARLY_PHASE1":4086,"PHASE1":4088,"PHASE2":4090,"PHASE3":4092,"PHASE4":4094,"NA":4096},{"trials":4087,"activeCount":98},[],{"trials":4089,"activeCount":98},[],{"trials":4091,"activeCount":98},[],{"trials":4093,"activeCount":98},[],{"trials":4095,"activeCount":98},[],{"trials":4097,"activeCount":98},[4098],{"nctId":4076,"briefTitle":4077,"status":140,"phases":4099,"start":4079,"enrollment":4080,"conditions":4100,"interventions":4101},[],[24,216],[4061,4083],{"intervention":4103,"totalTrials":94,"cells":4104},"[15-O]water",{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4111,"PHASE4":4113,"NA":4115},{"trials":4106,"activeCount":98},[],{"trials":4108,"activeCount":98},[],{"trials":4110,"activeCount":98},[],{"trials":4112,"activeCount":98},[],{"trials":4114,"activeCount":98},[],{"trials":4116,"activeCount":98},[4117],{"nctId":4118,"briefTitle":4119,"status":140,"phases":4120,"primaryCompletion":4121,"completion":4121,"start":4122,"enrollment":4123,"conditions":4124,"interventions":4126},"NCT00362843","Protein Synthesis in the Brain of Patients With Fragile X Syndrome",[],"2020-05-01","2006-08-22",147,[4125,112],"Fragile X Syndrome",[4103],{"intervention":4128,"totalTrials":94,"cells":4129},"Glucose",{"EARLY_PHASE1":4130,"PHASE1":4132,"PHASE2":4134,"PHASE3":4136,"PHASE4":4138,"NA":4140},{"trials":4131,"activeCount":98},[],{"trials":4133,"activeCount":98},[],{"trials":4135,"activeCount":98},[],{"trials":4137,"activeCount":98},[],{"trials":4139,"activeCount":98},[],{"trials":4141,"activeCount":98},[4142],{"nctId":4143,"briefTitle":4144,"status":140,"phases":4145,"start":4146,"enrollment":2730,"conditions":4147,"interventions":4149},"NCT00004451","Randomized Study of the Effects of Glucose on Cognition in Healthy Young and Elderly People and Parkinson's Disease Patients",[90],"1998-03",[4148],"Parkinson Disease",[4128],{"intervention":4151,"totalTrials":94,"cells":4152},"Naltrexone HCL\u002F Yohimbine HCL",{"EARLY_PHASE1":4153,"PHASE1":4155,"PHASE2":4157,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4154,"activeCount":98},[],{"trials":4156,"activeCount":98},[],{"trials":4158,"activeCount":98},[],{"trials":4160,"activeCount":98},[],{"trials":4162,"activeCount":98},[],{"trials":4164,"activeCount":98},[4165],{"nctId":4166,"briefTitle":4167,"status":140,"phases":4168,"completion":2485,"start":2729,"enrollment":357,"conditions":4169,"interventions":4171},"NCT00042536","Effects of Yohimbine and Naltrexone on Sexual Function",[],[4170],"Erectile Dysfunction",[4151],{"intervention":4173,"totalTrials":94,"cells":4174},"Transcranial Magnetic Stimulation Sham",{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4179,"PHASE3":4181,"PHASE4":4183,"NA":4185},{"trials":4176,"activeCount":98},[],{"trials":4178,"activeCount":98},[],{"trials":4180,"activeCount":98},[],{"trials":4182,"activeCount":98},[],{"trials":4184,"activeCount":98},[],{"trials":4186,"activeCount":98},[4187],{"nctId":4188,"briefTitle":4189,"status":140,"phases":4190,"primaryCompletion":4191,"completion":4192,"start":4193,"enrollment":4194,"conditions":4195,"interventions":4196},"NCT03027414","Effect of Transcranial Magnetic Stimulation to the Frontoparietal Attention Network on Anxiety Potentiated Startle",[90],"2019-07-19","2020-06-29","2017-01-23",61,[112],[4173],{"intervention":4198,"totalTrials":94,"cells":4199},"Sirolimus",{"EARLY_PHASE1":4200,"PHASE1":4202,"PHASE2":4204,"PHASE3":4206,"PHASE4":4208,"NA":4210},{"trials":4201,"activeCount":98},[],{"trials":4203,"activeCount":98},[],{"trials":4205,"activeCount":98},[],{"trials":4207,"activeCount":98},[],{"trials":4209,"activeCount":98},[],{"trials":4211,"activeCount":98},[4212],{"nctId":4213,"briefTitle":4214,"status":140,"phases":4215,"start":4216,"enrollment":4217,"conditions":4218,"interventions":4219},"NCT00001247","Inpatient Evaluation of Adults With Schizophrenia",[],"1989-09-15",648,[24],[4198],{"intervention":4221,"totalTrials":94,"cells":4222},"O15",{"EARLY_PHASE1":4223,"PHASE1":4225,"PHASE2":4227,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4224,"activeCount":98},[],{"trials":4226,"activeCount":98},[],{"trials":4228,"activeCount":98},[],{"trials":4230,"activeCount":98},[],{"trials":4232,"activeCount":98},[],{"trials":4234,"activeCount":98},[4235],{"nctId":4236,"briefTitle":4237,"status":140,"phases":4238,"completion":2728,"start":4239,"enrollment":325,"conditions":4240,"interventions":4241},"NCT00001917","Brain Imaging in Elderly People and Individuals With Alzheimer's Disease",[],"1999-04",[218,15],[4221,4242],"[F-18] FP-TZTP",{"intervention":4242,"totalTrials":94,"cells":4244},{"EARLY_PHASE1":4245,"PHASE1":4247,"PHASE2":4249,"PHASE3":4251,"PHASE4":4253,"NA":4255},{"trials":4246,"activeCount":98},[],{"trials":4248,"activeCount":98},[],{"trials":4250,"activeCount":98},[],{"trials":4252,"activeCount":98},[],{"trials":4254,"activeCount":98},[],{"trials":4256,"activeCount":98},[4257],{"nctId":4236,"briefTitle":4237,"status":140,"phases":4258,"completion":2728,"start":4239,"enrollment":325,"conditions":4259,"interventions":4260},[],[218,15],[4221,4242],{"intervention":3415,"totalTrials":94,"cells":4262},{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4271,"NA":4273},{"trials":4264,"activeCount":98},[],{"trials":4266,"activeCount":98},[],{"trials":4268,"activeCount":98},[],{"trials":4270,"activeCount":98},[],{"trials":4272,"activeCount":98},[],{"trials":4274,"activeCount":98},[4275],{"nctId":4276,"briefTitle":4277,"status":140,"phases":4278,"start":4279,"enrollment":1223,"conditions":4280,"interventions":4281},"NCT00942981","Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography",[],"2009-11-13",[734,24],[3415],{"intervention":4283,"totalTrials":94,"cells":4284},"[18F]SPA-RQ",{"EARLY_PHASE1":4285,"PHASE1":4287,"PHASE2":4289,"PHASE3":4291,"PHASE4":4293,"NA":4295},{"trials":4286,"activeCount":98},[],{"trials":4288,"activeCount":98},[],{"trials":4290,"activeCount":98},[],{"trials":4292,"activeCount":98},[],{"trials":4294,"activeCount":98},[],{"trials":4296,"activeCount":98},[4297],{"nctId":4298,"briefTitle":4299,"status":140,"phases":4300,"completion":2085,"start":706,"enrollment":357,"conditions":4301,"interventions":4302},"NCT00102102","Role of Substance P in Post-Traumatic Stress Disorder",[],[3902],[4283],{"intervention":547,"totalTrials":94,"cells":4304},{"EARLY_PHASE1":4305,"PHASE1":4307,"PHASE2":4309,"PHASE3":4311,"PHASE4":4313,"NA":4315},{"trials":4306,"activeCount":98},[],{"trials":4308,"activeCount":98},[],{"trials":4310,"activeCount":98},[],{"trials":4312,"activeCount":98},[],{"trials":4314,"activeCount":98},[],{"trials":4316,"activeCount":98},[4317],{"nctId":539,"briefTitle":540,"status":140,"phases":4318,"completion":542,"start":143,"enrollment":543,"conditions":4319,"interventions":4320},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":548,"totalTrials":94,"cells":4322},{"EARLY_PHASE1":4323,"PHASE1":4325,"PHASE2":4327,"PHASE3":4329,"PHASE4":4331,"NA":4333},{"trials":4324,"activeCount":98},[],{"trials":4326,"activeCount":98},[],{"trials":4328,"activeCount":98},[],{"trials":4330,"activeCount":98},[],{"trials":4332,"activeCount":98},[],{"trials":4334,"activeCount":98},[4335],{"nctId":539,"briefTitle":540,"status":140,"phases":4336,"completion":542,"start":143,"enrollment":543,"conditions":4337,"interventions":4338},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":552,"totalTrials":94,"cells":4340},{"EARLY_PHASE1":4341,"PHASE1":4343,"PHASE2":4345,"PHASE3":4347,"PHASE4":4349,"NA":4351},{"trials":4342,"activeCount":98},[],{"trials":4344,"activeCount":98},[],{"trials":4346,"activeCount":98},[],{"trials":4348,"activeCount":98},[],{"trials":4350,"activeCount":98},[],{"trials":4352,"activeCount":98},[4353],{"nctId":539,"briefTitle":540,"status":140,"phases":4354,"completion":542,"start":143,"enrollment":543,"conditions":4355,"interventions":4356},[90],[21],[546,547,548,549,550,551,552,533],{"intervention":4358,"totalTrials":94,"cells":4359},"Oxygen-15 Water",{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4364,"PHASE3":4366,"PHASE4":4368,"NA":4370},{"trials":4361,"activeCount":98},[],{"trials":4363,"activeCount":98},[],{"trials":4365,"activeCount":98},[],{"trials":4367,"activeCount":98},[],{"trials":4369,"activeCount":98},[],{"trials":4371,"activeCount":98},[4372],{"nctId":4373,"briefTitle":4374,"status":140,"phases":4375,"start":4376,"enrollment":4377,"conditions":4378,"interventions":4380},"NCT00001258","Studies of Frontal Lobe Brain Functioning in Schizophrenia",[],"1993-11-26",1039,[4379,24,4148],"Healthy Subjects",[4358]]